[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23315
1. Pereira SB, Thiel Rdo R, Riccetto C, Silva JM, Pereira LC, Herrmann V, Palma P: [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese]. Rev Bras Ginecol Obstet; 2010 Jun;32(6):273-8
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese].
  • [Transliterated title] Validação do International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) para a língua portuguesa.
  • PURPOSE: To translate, culturally adapt and validate the questionnaire "International Consultation on Incontinence Questionnaire Overactive Bladder" (ICIQ-OAB) for the Portuguese Language.
  • The final version of the ICIQ-OAB was applied together with the previously translated and tested version of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) in 142 male and female patients with irritative urinary symptoms.
  • CONCLUSION: The culturally adapted version of the ICIQ-OAB translated into Brazilian Portuguese presented satisfactory reliability and survey validity and was considered valid for the evaluation of irritative urinary symptoms of Brazilian patients of both genders.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder, Overactive / diagnosis. Urinary Incontinence / diagnosis

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20945012.001).
  • [ISSN] 1806-9339
  • [Journal-full-title] Revista brasileira de ginecologia e obstetrícia : revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
  • [ISO-abbreviation] Rev Bras Ginecol Obstet
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] Brazil
  •  go-up   go-down


2. Yagnik V, Chadha A, Chaudhari S, Patel K: Inflammatory myofibroblastic tumor of the urinary bladder. Urol Ann; 2010 May;2(2):78-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the urinary bladder.
  • Inflammatory myofibroblastic tumor (IMT) of bladder is an uncommon benign tumor of bladder, which is of unknown neoplastic potential, characterized by spindle cell proliferation with characteristic fibroinflammatory and pseudosarcomatous appearance.
  • Essential criteria for the diagnosis of IMT are: spindle myoepithelial cell proliferation and lymphocytic infiltrate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882160.001).
  • [ISSN] 0974-7834
  • [Journal-full-title] Urology annals
  • [ISO-abbreviation] Urol Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2943686
  • [Keywords] NOTNLM ; Immunohistochemical staining / inflammatory myofibroblastic tumor / spindle myoepithelial cell proliferation
  •  go-up   go-down


3. Ziadi S, Trimeche M, Hammedi F, Hidar S, Sriha B, Mestiri S, Korbi S: Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder. N Am J Med Sci; 2010 Jan;2(1):39-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral proliferating Brenner tumor of the ovary associated with recurrent urothelial carcinoma of the urinary bladder.
  • CONTEXT: Brenner tumors of ovary are relatively uncommon neoplasm.
  • Most of them are benign and less than 5% are proliferating or borderline.
  • The association between Brenner tumor of the ovary and papillary urothelial carcinoma of bladder is extremely rare.
  • CASE REPORT: We describe an unusual case of proliferating bilateral Brenner tumor of the ovary with a highly recurrent low-grade papillary urothelial carcinoma of bladder.
  • CONCLUSION: The immunohistopathological similarities of ovarian and bladder tumors and their association in the current case, may be coincidental but may reflect a common initiating event inducing similar pathogenesis changes in the epithelium of both organs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1961 Apr;81:743-51 [13684151.001]
  • [Cites] Urology. 2003 Mar;61(3):634-7; discussion 637 [12639661.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):268-71 [16832656.001]
  • [Cites] Cancer. 1979 May;43(5):1830-9 [445369.001]
  • [Cites] Pathologica. 1990 Jan-Feb;82(1077):101-8 [2194158.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(3):197-211 [2846458.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(3):233-4 [17624095.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(4):318-20 [10475132.001]
  • [Cites] Ann Pathol. 1998 Apr;18(2):103-9 [9608862.001]
  • [Cites] Mod Pathol. 1995 May;8(4):384-8 [7567935.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2692-7 [6722728.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1972;233:56-66 [5074634.001]
  • [Cites] Cancer. 1972 Jul;30(1):174-86 [5040741.001]
  • [Cites] Cancer. 1985 Aug 1;56(3):582-91 [4005815.001]
  • (PMID = 22624111.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3354386
  • [Keywords] NOTNLM ; Brenner tumor / ovary / urinary bladder / urothelial carcinoma
  •  go-up   go-down


Advertisement
4. Schwalenberg T, Neuhaus J, Horn LC, Alexander H, Zimmermann G, Ho Thi P, Mallock T, Stolzenburg JU: [New insights in the differential diagnosis of bladder pain syndrome]. Aktuelle Urol; 2010 Mar;41(2):107-18
MedlinePlus Health Information. consumer health - Interstitial Cystitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New insights in the differential diagnosis of bladder pain syndrome].
  • [Transliterated title] Neue Erkenntnisse zur Differenzialdiagnostik des Bladder-Pain-Syndroms.
  • The diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC) is challenging, since pathogenetic mechanisms and the definition of clinical relevant parameters are still under lively discussion.
  • The criteria recently proposed by the European Society for the Study of Interstitial Cystitis (ESSIC) define a collective of patients based on the cardinal symptom of bladder pain which is heterogeneous, and therefore cannot receive standardised consistent therapy.
  • Thus an extended diagnosis based on molecular markers seems to be indicated to render individual pharmacotherapy possible, and to contribute to elucidation of BPS/IC pathogenesis.
  • For this purpose we feel the vital need for taking a bladder biopsy.
  • The diagnosis of BPS/IC should rely on 3 "columns":.
  • Since a significant contribution of the 3 functional units of the bladder to the pathophysiology is most evident, the examinations should ideally include urothelium, lamina propria, and detrusor musculature.
  • [MeSH-major] Cystitis, Interstitial / diagnosis
  • [MeSH-minor] Biopsy. Capillaries / pathology. Capillaries / physiopathology. Chorionic Gonadotropin, beta Subunit, Human / genetics. Cystoscopy. Diagnosis, Differential. Gene Expression / physiology. Humans. Mast Cells / pathology. Mast Cells / physiology. Mucous Membrane / pathology. Mucous Membrane / physiopathology. Nerve Fibers / pathology. Nerve Fibers / physiology. Practice Guidelines as Topic. Receptors, G-Protein-Coupled / genetics. Risk Factors. Urinary Bladder / pathology. Urinary Bladder / physiopathology. Urinary Bladder, Overactive / classification. Urinary Bladder, Overactive / pathology. Urinary Bladder, Overactive / physiopathology. Urothelium / pathology. Urothelium / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart New York.
  • (PMID = 20309783.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Receptors, G-Protein-Coupled
  • [Number-of-references] 52
  •  go-up   go-down


5. Fu TY, Tu MS, Tseng HH, Wang JS: Overexpression of p27kip1 in urinary bladder urothelial carcinoma. Int J Urol; 2007 Dec;14(12):1084-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of p27kip1 in urinary bladder urothelial carcinoma.
  • OBJECTIVES: Cyclins and cyclin-dependent kinase (CDK) complexes have important regulatory roles during cell cycle progression and can be used as prognostic markers in various kinds of malignant tumors.
  • This study investigated the expression of proliferative cell nuclear antigen (PCNA), p53, Rb, p27(kip1), and cyclin D1 by immunostains in bladder tumors, especially urothelial papilloma, papillary urothelial neoplasm of low malignant potential, and low and high grade urothelial carcinoma, to see if their expression is associated with classification or grading of the urinary bladder urothelial carcinoma.
  • METHOD: Nuclear expression of PCNA, p53, Rb, p27(kip1), and cyclin D1 was determined immunohistochemically in a series of 89 urinary bladder tumor specimens, including 13 papilloma, 15 urothelial neoplasm of low malignant potential, 17 low grade urothelial carcinoma, and 44 high grade urothelial carcinoma.
  • The results of immunoreactivity were analyzed with respect to the associations with tumor grade.
  • RESULTS: Eighty-two percent (38/45) of the p27(kip1) positive tumors were urothelial carcinoma, and the percentage of the p27(kip1) positivity was higher with increasing grade of the urothelial carcinoma (P = 0.011).
  • There was no significant difference in cyclinD1, Rb and PCNA expression between benign, low malignant potential and urothelial carcinoma.
  • CONCLUSION: We first noted an overexpression of p27(kip1) in urinary bladder urothelial carcinoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Intracellular Signaling Peptides and Proteins / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036045.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cyclin D; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proliferating Cell Nuclear Antigen; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


6. Haferkamp A, Hohenfellner M: [Intravesical treatment of overactive bladder syndrome]. Urologe A; 2006 Oct;45(10):1283-8
Hazardous Substances Data Bank. OXYBUTYNIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravesical treatment of overactive bladder syndrome].
  • [Transliterated title] Intravesikale Therapie des Overactive-bladder-Syndroms.
  • Overactive bladder and urgency incontinence are common conditions generally treated with oral anticholinergic medication.
  • Botulinum toxin type A injections into the detrusor have been shown to increase bladder capacity and to decrease detrusor overactivity for 6 or more months.
  • Intravesical local anesthetics such as lidocaine and bupivacaine block the conduction of unmyelinated C fibers which results in an increase of functional bladder capacity.
  • Intravesical capsaicin and resiniferatoxin also affect the afferent C fiber innervation of the bladder, leading to a decrease in detrusor overactivity and also an increased bladder capacity.
  • In conclusion, intravesical therapies can provide an alternative treatment for the management of overactive bladder.
  • [MeSH-major] Administration, Intravesical. Cholinergic Antagonists / administration & dosage. Muscarinic Antagonists / administration & dosage. Urinary Bladder, Overactive / drug therapy. Urinary Incontinence / drug therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1995 Nov;102(11):929-30 [8534633.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):60-4; discussion 66 [10767456.001]
  • [Cites] J Urol. 1992 Aug;148(2 Pt 2):595-7 [1640530.001]
  • [Cites] J Urol. 1989 Jun;141(6):1350-2 [2724432.001]
  • [Cites] J Urol. 2002 Nov;168(5):1897-913 [12394674.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):692-7 [10953127.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):54-7 [2026301.001]
  • [Cites] Int Braz J Urol. 2004 Jan-Feb;30(1):53-8 [15707518.001]
  • [Cites] Lancet. 1992 May 16;339(8803):1239 [1349978.001]
  • [Cites] Curr Urol Rep. 2005 Nov;6(6):429-33 [16238916.001]
  • [Cites] Neurourol Urodyn. 2005;24(3):231-6 [15747344.001]
  • [Cites] J Urol. 2003 May;169(5):1892-5 [12686868.001]
  • [Cites] Arzneimittelforschung. 1998 May;48(5):486-91 [9638316.001]
  • [Cites] BJU Int. 2005 May;95(7):1023-7 [15839924.001]
  • [Cites] J Urol. 2005 Sep;174(3):984-9 [16094019.001]
  • [Cites] Am J Obstet Gynecol. 2005 May;192(5):1735-40 [15902187.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):88-93; discussion 93-4 [15183552.001]
  • [Cites] J Urol. 2005 Sep;174(3):977-82; discussion 982-3 [16094018.001]
  • [Cites] J Med Assoc Thai. 2003 Sep;86(9):861-7 [14649971.001]
  • [Cites] Urology. 2005 Jul;66(1):82-7 [15992872.001]
  • [Cites] J Urol. 2000 Aug;164(2):340-3 [10893580.001]
  • [Cites] Urology. 2000 May;55(5A Suppl):33-46; discussion 50 [10767450.001]
  • [Cites] J Obstet Gynaecol. 2006 Feb;26(2):141-3 [16483973.001]
  • [Cites] Neurourol Urodyn. 1999;18(5):447-53 [10494116.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1988 Aug;48(8):562-6 [3215450.001]
  • (PMID = 16972089.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Cholinergic Antagonists; 0 / Mandelic Acids; 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; EC 3.4.24.69 / Botulinum Toxins, Type A; K9P6MC7092 / oxybutynin
  • [Number-of-references] 26
  •  go-up   go-down


7. Lopez-Beltran A, Requena MJ, Cheng L, Montironi R: Pathological variants of invasive bladder cancer according to their suggested clinical significance. BJU Int; 2008 Feb;101(3):275-81
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological variants of invasive bladder cancer according to their suggested clinical significance.
  • Several pathological variants of bladder cancer, reflecting tumour heterogeneity in urothelial carcinoma, have been recently recognized.
  • It is important for both pathologists and urologists to be aware of the diverse morphological patterns in invasive bladder cancer, as they might be relevant in patient management and prognosis, mainly because they can mimic benign lesions, secondary tumours or might require a specific therapeutic approach.
  • [MeSH-major] Carcinoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986288.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 71
  •  go-up   go-down


8. Bensalah K, Patard JJ: [Management of T1G3 tumours of the bladder]. Ann Urol (Paris); 2006 Apr;40(2):93-100
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of T1G3 tumours of the bladder].
  • [Transliterated title] Prise en charge des tumeurs de vessie T1G3 management of T1G3 tumours of the bladder.
  • T1G3 tumours are the most aggressive superficial tumours of the bladder, with a high risk of recurrence and progression.
  • Complete endoscopic resection of the tumour is the first diagnostic and therapeutic step in T1G3 management.
  • A second resection should be done at 1 month to avoid residual tumour and misdiagnosis of a muscle infiltrative cancer.
  • As a result of treatment by instillations of Calmette and Guérin bacillus following endoscopic resection, a 5-year survival rate of 80% has been reported, with 50 to 60% of bladder preservation.
  • BCG is the only conservative treatment that has proven effectiveness on both tumour recurrence and progression.
  • Radical cystectomy can be chosen as first line treatment in patients with particularly aggressive tumours.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. BCG Vaccine / therapeutic use. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709007.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  • [Number-of-references] 58
  •  go-up   go-down


9. Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E: [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer]. Arch Esp Urol; 2008 Apr;61(3):377-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].
  • [Transliterated title] Empleo del NMP22 Bladder-Chek en el diagnóstico y seguimiento del cáncer de vejiga.
  • OBJECTIVES: The goal of this work is to evaluate the usefulness of NMP22 BladderChek in the diagnosis and follow-up of bladder cancer, comparing it with cystoscopy and urine cytology.
  • METHODS: Group 1: 109 asymptomatic patients on follow up for bladder cancer underwent cystoscopy, cytology and NMP22 BladderChek.
  • RESULTS: Group 1: 9 patients had tumor relapse.
  • Group 2: 12 patients had bladder cancer.
  • CONCLUSIONS: The low sensitivity of NMP22 Bladder-Chek invalidates it as alternative method to cystoscopy in the follow-up of bladder cancer.
  • But it can be recommended for screening in patients without history of bladder cancer but with an increased risk (smokers, patients with dysuria and hematuria).
  • [MeSH-major] Biomarkers, Tumor / urine. Neoplasm Recurrence, Local / diagnosis. Nuclear Proteins / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Cystoscopy. Cytodiagnosis. Female. Hematuria / etiology. Hematuria / urine. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Reagent Strips

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581675.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Strips; 0 / nuclear matrix protein 22
  •  go-up   go-down


10. Aguilera Tubet C, Gutiérrez Baños JL, Antolín Juárez F, Rebollo Rodrigo MH, Portillo Martín JA, Ruiz Izquierdo F, Ballestero Diego R, Martín García B: [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma]. Actas Urol Esp; 2005 Mar;29(3):252-6
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study between cystoscopy, urinary cytology, NMP-22 and a new method, bladder chek, in the follow-up of superficial bladder cell carcinoma].
  • [Transliterated title] Estudio comparativo entre cistoscopia, citología urinaria, NMP-22 y un nuevo método, bladder chek, en el seguimiento del cáncer vesical superficial.
  • OBJECTIVE: The goal of this work tries to evaluate the utility of the qualitative determination of NMP-22 in the evaluation of the superficial bladder carcinoma in asymptomatic patients, comparing it with its quantitative determination, the cytology and the cystoscopy.
  • MATERIALS AND METHODS: A simple of urine just voided was taken in 88 asymptomatic patient follow-up for superficial bladder cell carcinoma.
  • This dose was distributed in 3 parts, for performed cytology, for determination of NMP-22, and 4 drops of the third part are added to device bladder chek.
  • Later, we performed cystoscopy and transurethral resection in patients with a suspicion of bladder cancer.
  • RESULTS: 26 patients had tumor relapse and 62 patients were free of disease.
  • The sensitivity for the bladder chek was of 28%, 34.62% for NMP-22, 34.62% for cytology and 100% for cystoscopy.
  • The sensitivity by degree was 25 in G1, 28.57 in G2 and 50 in G3 for Bladder chek; 29.41, 42.86 and 50 for NMP-22; 23.53, 71.43 and 0 for cytology.
  • The sensitivity by stages was 27.7 in Ta-1 and 50 in T2 for Bladder chek; 34.78 and 50 for NMP-22; 39.13 and 0 for the cytology.
  • CONCLUSIONS: The low sensitivity of bladder chek invalidates it like alternative method to the cystoscopy in the follow-up of the superficial asymptomatic bladder cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Cystoscopy. Immunologic Tests. Nuclear Proteins / analysis. Urinary Bladder Neoplasms / diagnosis. Urine / cytology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15945249.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


11. Gaunez N, Larré S, Pirès C, Doré B, Wei J, Pfister C, Irani J: [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)]. Prog Urol; 2010 May;22(6):350-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [French translation and linguistic validation of the questionnaire Bladder Cancer Index (BCI)].
  • [Transliterated title] Traduction en langue française et validation linguistique de l'auto-questionnaire Bladder Cancer Index évaluant la qualité de vie dans les tumeurs de vessie.
  • OBJECTIVE: Translation and linguistic validation of the French version of Bladder Cancer Index (BCI).
  • MATERIAL AND METHODS: A double-back translation of the original Bladder Cancer Index was performed.
  • Finally, a pilot study followed by an interview was carried out among one woman and five men having bladder cancer.
  • The impact of various bladder cancer treatment on quality of life could hence be assessed and compared.
  • [MeSH-major] Surveys and Questionnaires. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22541905.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Validation Studies
  • [Publication-country] France
  •  go-up   go-down


12. Thiel DD, Williams BF, Krishna M, Leroy TJ, Igel TC: Robot-assisted laparoscopic excision of bladder wall leiomyoma. J Endourol; 2009 Apr;23(4):579-82; discussion 582
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic excision of bladder wall leiomyoma.
  • Leiomyoma is the most frequent nonepithelial benign tumor of the bladder, and only about 170 cases have been reported in the literature.
  • Most bladder wall leiomyomas are found incidentally and can be clinically followed if imaging and biopsy findings are consistent with the diagnosis.
  • Resection is usually performed for symptomatic or enlarging masses and is indicated if the diagnosis is in question.
  • We demonstrate imaging characteristics, port placement, operative technique, and surgical pathologic findings of the first reported case of robot-assisted laparoscopic resection of a bladder wall leiomyoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19335142.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Wang CL, Tsai EM, Liu CM, Wu CH, Long CY: Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure. Gynecol Obstet Invest; 2007;63(1):28-30
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure.
  • However, concomitant resection of a bladder tumor during the TVT procedure is rare.
  • A bladder tumor located in the trigone was found incidentally during cystoscopy.
  • Concomitant resection of the bladder tumor was performed following the TVT procedure.
  • The surgical result of our patient suggests that concomitant resection of a benign intravesical pathology with TVT procedure is safe and effective.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Incontinence, Stress / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864984.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


14. Gómez García I, Molina Burgos R, Fernández Fernández E, Palacio España A, González Chamorro F, Alvarez E, Conde Someso S: [Myofibroblastic tumor of bladder]. Actas Urol Esp; 2005 Jun;29(6):611-4
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myofibroblastic tumor of bladder].
  • [Transliterated title] Tumor miofibroblástico de vejiga.
  • The myofibroblastic tumor, is a mesenchymal benign tumor of exceptional character, being its localization but habitual it is the lung; while its appearance in the bladder, is exceptional, not existing but of 100 published cases, of this tumor type in the bladder.
  • This tumor type that clinic and radiologics, behave as a wicked tumor.
  • The pathological diagnosis is complex, due to its similarity with the sarcomas, being necessary to appeal to the inmunohistochemics for a I diagnose of certainty.
  • We present a new case of this neoplasm, carrying out a wide bibliographical revision.
  • [MeSH-major] Granuloma, Plasma Cell / diagnosis. Urinary Bladder Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16092689.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


15. Tunca F, Sanli O, Demirkol K, Gulluoglu M: Inflammatory pseudotumor of urachus mimicking invasive carcinoma of bladder. Urology; 2006 Mar;67(3):623.e1-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of urachus mimicking invasive carcinoma of bladder.
  • Inflammatory pseudotumor of the bladder is a rare benign lesion of unknown etiology.
  • This benign condition mimics invasive malignant tumors of the urinary bladder, and aggressive surgery is the basic treatment modality.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Granuloma, Plasma Cell / diagnosis. Urachus. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Diagnostic Errors. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527590.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Herr H, Konety B, Stein J, Sternberg CN, Wood DP Jr: Optimizing outcomes at every stage of bladder cancer: do we practice it? Urol Oncol; 2009 Jan-Feb;27(1):72-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing outcomes at every stage of bladder cancer: do we practice it?
  • Bladder cancer is a heterogeneous disease that can be either relatively benign or highly malignant depending on the grade and stage of the tumor.
  • Determining the best practices for bladder cancer is based on the stage, grade, and presentation of the cancer.
  • Herein we identify four clinical scenarios involving bladder cancer and discuss whether best practice guidelines are available for these clinical scenarios, and if so, how often do we follow these guidelines.
  • [MeSH-major] Medical Oncology / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Clinical Trials as Topic. Cost-Benefit Analysis. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Neoplasm Invasiveness. Outcome Assessment (Health Care). Urology / methods

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111802.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


17. Lopez-Beltran A: Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl; 2008 Sep;(218):95-109
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer: clinical and pathological profile.
  • Bladder tumours represent a heterogeneous group of cancers.
  • The natural history of these bladder cancers is that of recurrence of disease and progression to higher grade and stage disease.
  • Furthermore, recurrence and progression rates of superficial bladder cancer vary according to several tumour characteristics, mainly tumour grade and stage.
  • The most recent World Health Organization (WHO) classification of tumours of the urinary system includes urothelial flat lesions: flat hyperplasia, dysplasia and carcinoma in situ.
  • The papillary lesions are broadly subdivided into benign (papilloma and inverted papilloma), papillary urothelial neoplasia of low malignant potential (PUNLMP) and non-invasive papillary carcinoma (low or high grade).
  • Whether PUNLMP remains a clinically useful category, or whether this category should be expanded to include all low-grade, stage Ta lesions (PUNLMP and low-grade papillary carcinoma) as a wider category of less aggressive tumours not labelled as cancer, needs to be discussed in the near future.
  • This article summarizes the recent literature concerning important issues in the pathology and the clinical management of patients with bladder urothelial carcinoma.
  • Emphasis is placed on clinical presentation, the significance of haematuria, macroscopic appearance (papillary, solid or mixed, single or multiple) and synchronous or metachronous presentation (field disease vs monoclonal disease with seeding), classification and microscopic variations of bladder cancer with clinical significance, TNM distribution and the pathological grading according to the 2004 WHO proposal.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Hyperplasia. Neoplasm Staging. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815924.001).
  • [ISSN] 0300-8886
  • [Journal-full-title] Scandinavian journal of urology and nephrology. Supplementum
  • [ISO-abbreviation] Scand J Urol Nephrol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 100
  •  go-up   go-down


18. Mamoon N, Iqbal MA, Jamal S, Luqman M: Urothelial neoplasia of the urinary bladder--comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998. J Ayub Med Coll Abbottabad; 2006 Apr-Jun;18(2):4-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial neoplasia of the urinary bladder--comparison of interobserver variability for WHO Classification 1972 with WHO/ISUP Consensus Classification 1998.
  • BACKGROUND: Classification of urothelial bladder tumours is an important factor in the treatment and prognosis of these lesions.
  • The objective of this study was to classify urothelial neoplasms of the urinary bladder using the latest WHO/ISUP Consensus Classification 1998 and WHO Classification 1972 and compare the two regarding interobserver variability.
  • METHODS: This study included 100 consecutive biopsy specimens of urothelial neoplasms of the urinary bladder diagnosed at the department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi.
  • The tumour categories for WHO classification 1972; papilloma, and transitional cell carcinoma (TCC) grades I, II and III were compared with the WHO/ISUP Consensus Classification entities of papilloma, papillary neoplasm of low malignant potential, low grade and high grade papillary carcinomas.
  • RESULTS: There was agreement on 80 tumours between the two groups of histopathologists when using WHO classification 1972 while there was agreement on 95 tumours using WHO/ISUP consensus classification.
  • Kappa values were less for benign and borderline lesions using both systems.
  • CONCLUSIONS: WHO/ISUP Consensus Classification 1998 showed less interobserver variability than WHO Classification 1972 in the evaluation of bladder tumours.
  • There was less agreement on the benign and borderline lesions using both the classifications.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977804.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


19. Carrieri G, Corvasce T, Annese P, Tolve I, Caniglia A, Di Sabato G: Endoscopic treatment of a large leiomyoma of the bladder. Arch Ital Urol Androl; 2005 Jun;77(2):111-2
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic treatment of a large leiomyoma of the bladder.
  • Leiomyoma is a benign neoplasm rarely found in the bladder.
  • We present a case of a large leiomyoma of the bladder treated successfully by endoscopic transurethral resection.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146274.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Tamas EF, Stephenson AJ, Campbell SC, Montague DK, Trusty DC, Hansel DE: Histopathologic features and clinical outcomes in 71 cases of bladder diverticula. Arch Pathol Lab Med; 2009 May;133(5):791-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic features and clinical outcomes in 71 cases of bladder diverticula.
  • CONTEXT: Bladder diverticula often come to clinical attention when complications or malignancy occur, although limited information is available regarding histopathologic features and clinical outcomes.
  • OBJECTIVE: To identify the morphologic findings, neoplastic subtypes, and clinical outcomes by reviewing all bladder diverticula that underwent pathologic sampling for primary diverticular processes at the Cleveland Clinic.
  • DESIGN: Hematoxylin-eosin slides from 71 cases of bladder diverticula were reviewed.
  • Follow-up for patients with benign findings demonstrated no subsequent neoplastic bladder disease.
  • CONCLUSIONS: Patients with invasive carcinoma in diverticula have an increased frequency of less-common bladder cancer subtypes, and those with pT3 disease are at increased risk for subsequent progression.
  • [MeSH-major] Diverticulum / pathology. Urinary Bladder / pathology. Urinary Bladder Diseases / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Small Cell / complications. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urothelium / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415955.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Jalpota Y, Tewari V, Madan R: Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):261-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent nephrogenic adenoma of urinary bladder in a renal allograft recipient--a case report.
  • Nephrogenic adenoma is a rare benign tumour-like lesion within the urothelial mucosa of the urinary tract.
  • It may be an incidental finding in bladder of a patient presenting with haematuria, dysuria and bladder growth after renal allograft transplant.
  • Clinically it mimics bladder neoplasm.
  • Definite diagnosis is established by histological examination of tumor.
  • Though it attains an extensive spread in bladder mucosa and has a high tendency to recur, the clinical course is benign.
  • [MeSH-major] Adenoma / pathology. Kidney Neoplasms. Neoplasm Recurrence, Local / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933732.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


22. Scosyrev E, Trivedi D, Messing E: Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol; 2010 Sep;20(5):404-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female bladder cancer: incidence, treatment, and outcome.
  • PURPOSE OF REVIEW: Women are generally less likely to develop bladder cancer compared with men; however, once they acquire this disease, they have a less favorable prognosis.
  • In this review, we describe our current understanding of the relationship between sex and bladder cancer incidence and outcomes and discuss the most recent developments in this area of research.
  • RECENT FINDINGS: Despite some evidence suggesting involvement of hormonal factors in bladder cancer carcinogenesis, the exact mechanisms responsible for increased bladder cancer incidence in men are still incompletely understood.
  • It has been hypothesized that women present with more advanced stages (and thus have inferior survival) than men because early signs of bladder cancer in women are often attributed to more common benign conditions.
  • However, recent studies have shown that excess mortality in women persists after adjustment for stage and other tumor characteristics.
  • Women also do not appear to be significantly undertreated for bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms. Women's Health
  • [MeSH-minor] Female. Health Status Disparities. Humans. Incidence. Male. Neoplasm Staging. Risk Assessment. Risk Factors. Sex Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Women's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592613.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Abbas F, Memon A, Siddiqui T, Kayani N, Ahmad NA: Granular cell tumors of the urinary bladder. World J Surg Oncol; 2007;5:33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumors of the urinary bladder.
  • BACKGROUND: Granular cell tumors (GCTs) are extremely rare lesions of the urinary bladder with only nine cases being reported in world literature of which one was malignant.
  • Generally believed to be of neural origin based on histochemical, immunohistochemical, and ultrastructural studies; they mostly follow a clinically benign course but are commonly mistaken for malignant tumors since they are solid looking, ulcerated tumors with ill-defined margins.
  • MATERIALS AND METHODS: We herein report two cases of GCTs, one benign and one malignant, presenting with gross hematuria in a 14- and a 47-year-old female, respectively.
  • The benign tumor was successfully managed conservatively with transurethral resection alone while for the malignant tumor, radical cystectomy, hysterectomy with bilateral salpingo-oophorectomy, anterior vaginectomy, plus lymph node dissection was done.
  • CONCLUSION: We recommend careful pathologic assessment for establishing the appropriate diagnosis and either a conservative or aggressive surgical treatment for benign or localized malignant GCT of the urinary bladder, respectively.
  • [MeSH-major] Cystoscopy / methods. Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Neoplasm Invasiveness / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Emergency Service, Hospital. Female. Follow-Up Studies. Hematuria / diagnosis. Hematuria / etiology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1973 Feb;109(2):101-11 [4124410.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1963 Oct;16:1202-13 [14079990.001]
  • [Cites] Br J Urol. 1961 Mar;33:76-9 [13683165.001]
  • [Cites] J Laryngol Otol. 1998 Apr;112(4):373-6 [9659502.001]
  • [Cites] Am J Surg Pathol. 1991 Jan;15(1):48-58 [1985501.001]
  • [Cites] Br J Urol. 1985 Feb;57(1):109-10 [2982445.001]
  • [Cites] J Pathol. 1984 Mar;142(3):221-9 [6323661.001]
  • [Cites] Am J Pathol. 1983 Aug;112(2):139-46 [6192721.001]
  • [Cites] Cancer. 1982 Apr 15;49(8):1624-8 [6175391.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;386(2):239-48 [7189308.001]
  • [Cites] J Urol. 1974 Sep;112(3):343-5 [4368755.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:936-54 [13893237.001]
  • [Cites] Am J Clin Pathol. 1971 Dec;56(6):736-49 [4108241.001]
  • [Cites] Cancer. 1971 Apr;27(4):948-55 [4102365.001]
  • [Cites] Hinyokika Kiyo. 1969 Jul;15(7):505-13 [4310526.001]
  • [Cites] J Urol. 1968 Dec;100(6):735-7 [4301412.001]
  • [Cites] Int J Urol. 2001 Jan;8(1):29-31 [11168695.001]
  • [Cites] BJU Int. 1999 Nov;84(7):871-2 [10532990.001]
  • (PMID = 17355632.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1828733
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


24. Uchikoba T, Horiuchi K, Oka F, Sato M, Tsuboi N, Ohaki Y, Nishimura T: Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride. Urol Int; 2005;74(3):235-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosing the location of carcinoma in situ (CIS) of the urinary bladder using pirarubicin hydrochloride.
  • INTRODUCTION: No established technique for locating solitary carcinoma in situ (CIS) of the urinary bladder or CIS accompanying bladder cancer has been determined.
  • Here we investigated whether the location of CIS of the urinary bladder can be macroscopically ascertained by instilling pirarubicin hydrochloride (THP) into the urinary bladder.
  • PATIENTS AND METHODS: We dissolved 50 mg of THP in 50 ml of distilled water, and instilled the resulting solution into the urinary bladder.
  • After 5 min, the urinary bladder is examined using a cystoscope.
  • RESULTS: THP uptake was seen in 19 flat (nontumorous) areas of the bladder mucosa in 13 patients.
  • THP uptake was also seen in flat malignant lesions such as bladder cancer invasion into the prostatic urethra, and in benign lesions such as chronic cystitis and urothelial hyperplasia.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Doxorubicin / analogs & derivatives. Immunosuppressive Agents. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Biopsy. Cystoscopy. Female. Humans. Male. Microscopy, Fluorescence. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / ultrastructure. Neoplasm Staging. Sensitivity and Specificity. Urinary Bladder / metabolism. Urinary Bladder / ultrastructure

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15812210.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


25. Mitropoulos D, Kiroudi-Voulgari A, Nikolopoulos P, Manousakas T, Zervas A: Accuracy of cystoscopy in predicting histologic features of bladder lesions. J Endourol; 2005 Sep;19(7):861-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of cystoscopy in predicting histologic features of bladder lesions.
  • PURPOSE: To correlate individual endoscopist impressions of the nature (benign/malignant) of a urothelial lesion and, in the case of malignancy, "clinical" grade and stage of bladder lesions with the histologic findings after transurethral biopsy/resection.
  • PATIENTS AND METHODS: We considered 146 patients submitted to cystoscopy and transurethral excision of tumors or biopsy of suspect regions.
  • Both specialists and trainees had a tendency to overdiagnose bladder cancer, and they were not effective in predicting the precise stage: complete agreement with the pathologic stage was observed in 66.1% and 64.5% of cases, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190845.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Menéndez V, Fernández-Suárez A, Galán JA, Pérez M, García-López F: Diagnosis of bladder cancer by analysis of urinary fibronectin. Urology; 2005 Feb;65(2):284-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of bladder cancer by analysis of urinary fibronectin.
  • OBJECTIVES: To evaluate the diagnostic efficacy of the analysis of fibronectin in the urine samples of patients with bladder cancer.
  • METHODS: The study included 123 subjects: one group of 68 patients with bladder cancer confirmed by transurethral resection; a second group of 10 patients with benign urologic disease, and a third group of 45 healthy subjects.
  • We carried out the analysis of bladder tumor fibronectin (BTF), cytology, and creatinine in urine, and calculated the BTF/creatinine (BTF/CREA) ratio.
  • The sensitivity of urinary cytology was only 55%, but the specificity was 100%.
  • The patients with bladder cancer had significantly greater levels of BTF and the BTF/CREA ratio than did the healthy subjects (P <0.001) and, in the case of BTF without correcting for creatinine, than did the patients with benign urologic disease (P <0.05).
  • We also found significant differences in the levels of BTF and the BTF/CREA ratio among tumor stages, degree of differentiation, tumor size, multifocal nature, and macroscopic appearance.
  • CONCLUSIONS: Determination of fibronectin could be a useful test in the diagnosis of bladder tumors.
  • Nevertheless, the utility of BTF needs to be studied in a wider way in the presence of other pathologic features concurrent with bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Transitional Cell / urine. Fibronectins / urine. Neoplasm Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Creatinine / urine. Humans. Luminescent Measurements. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / urine. Predictive Value of Tests. Prognosis. Prospective Studies. ROC Curve. Sensitivity and Specificity. Urine / cytology. Urologic Diseases / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708039.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / Neoplasm Proteins; AYI8EX34EU / Creatinine
  •  go-up   go-down


27. Gaisa NT, Henkel C, Knüchel R: Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls. Curr Opin Urol; 2010 Sep;20(5):398-403
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour node metastasis staging of bladder cancer: prognosis versus pitfalls.
  • PURPOSE OF REVIEW: The WHO classification of urothelial cancer in 2004 has made changes based on the insights of molecular genetics, indicating bladder cancer with entities that are genetically stable versus those that are genetically instable.
  • Clinical studies based on solid histological diagnosis are as necessary as the definition of more molecular features of bladder cancer.
  • RECENT FINDINGS: Solid histological diagnosis includes sufficient clinical information and adequate tissue processing.
  • This combined with molecular data will lead to a more clear-cut distinction between benign and malignant and possibly to another change in terminology with higher concordance to other epithelial tumours.
  • Whereas the identification of FGFR3 mutations has led to a better distinction of at least two pathways of urothelial carcinogenesis, additional multiparametric approaches may help improve the still inadequate search for urine and blood markers indicative of bladder cancer and/or its progression.
  • SUMMARY: Recent data mainly support the concept of the WHO 2004 classification of bladder cancer.
  • We are optimistic that an even more clear-cut distinction between benign recurring, nonprogressing tumours and more aggressive tumours will enable us to focus and limit chemotherapy.
  • [MeSH-major] Lymph Nodes / pathology. Neoplasm Staging. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Molecular Diagnostic Techniques. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Reproducibility of Results

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20625299.001).
  • [ISSN] 1473-6586
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


28. Riesz P, Székely E, Törzsök P, Majoros A, Szendroi A, Dombovári P, Romics I: [Can inverted papilloma in urinary bladder be considered as a benign tumor]. Orv Hetil; 2010 Jan 17;151(3):92-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Can inverted papilloma in urinary bladder be considered as a benign tumor].
  • [Transliterated title] Jóindulatú daganat-e a húgyhólyag invertált papillomája?
  • Inverted papilloma of the urinary bladder is a rare entity.
  • They aimed to find out the rate of inverted papilloma recurrences, and transformations into malignant bladder cancer.
  • MATERIALS AND METHODS: Thirty patients with histologically proven inverted papilloma were followed after transurethral resection of bladder, which meant urine tests every three months, abdominal ultrasound and cystoscopy.
  • In one case, inverted papilloma and transitiocellular tumor (pTa G1) were detected.
  • In one patient, inverted papilloma was found by control cystoscopy after transurethral resection of bladder (pT1 G2) and local chemotherapy 15 months later.
  • CONCLUSIONS: Based on authors' experience, inverted papilloma of the urinary bladder is a benign lesion, but malignant changes or concomitant transitiocellular tumor may occur, thus follow-up is needed.
  • Although references are not standardized, authors suggest following patients with inverted papilloma as a primary (pTa G1) bladder cancer.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Papilloma, Inverted / pathology. Papilloma, Inverted / surgery. Precancerous Conditions / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061266.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


29. Zani D, Simeone C, Cosciani Cunico S, da Pozzo GP: [Fluorescence endoscopy in the diagnosis and treatment of superficial bladder neoplasms]. Minerva Urol Nefrol; 2005 Dec;57(4):335-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fluorescence endoscopy in the diagnosis and treatment of superficial bladder neoplasms].
  • [Transliterated title] L'indagine fotodinamica nella diagnosi e nel trattamento della neoplasia vseicale superficiale.
  • AIM: The results of a clinical investigation on neoplasm and bladder dysplasia detection by 5-aminolaevulinic acid (5-ALA)-induced fluorescence are reported.
  • In this paper the authors report their experience with 5-ALA in the diagnosis, treatment and follow-up of bladder neoplasms after chemotherapy and endocavitary immunotherapy.
  • METHODS: The 5-ALA was instilled in the bladder 2 h before bladder transurethral resection.
  • RESULTS: One-hundred and four benign and 92 malignant/dysplastic areas were biopsied; 46 malignant/dysplastic lesions were not detected during routine white-light cystoscopy but were identified with fluorescence cystoscopy.
  • [MeSH-major] Aminolevulinic Acid. Cystoscopy / methods. Photosensitizing Agents. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247356.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


30. Zachariou AG, Manoliadis IN, Kalogianni PA, Karagiannis GK, Georgantzis DJ: A rare case of bladder fibroepithelial polyp in childhood. Arch Ital Urol Androl; 2005 Jun;77(2):118-20
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of bladder fibroepithelial polyp in childhood.
  • OBJECTIVE: To present a rare case of a benign polyp in a child.
  • Very few cases of urinary tract fibroepithelial polyps in the bladder are reported in the international literature and they are even less common in children.
  • The patient did not report previous urinary tract disorders.
  • After a thorough laboratory investigation, which included urinalysis, urine culture, ultrasonography, intravenous pyelography and cystoscopy the presence of an exophytic papillary tumor in the bladder was identified.
  • RESULTS: The biopsy set the diagnosis of fibroepithelial polyp, which is a rare benign neoplasm and occurs in patients of nearly all ages.
  • They are rarely found in the bladder, especially in the childhood.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146277.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Herr H, Donat M, Dalbagni G, Taylor J: Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability. BJU Int; 2010 Jul;106(1):53-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability.
  • STUDY TYPE: Diagnosis (exploratory cohort) Level of Evidence 2b.
  • OBJECTIVE: To assess individual urologist variability using narrow-band imaging (NBI) cystoscopy to evaluate bladder tumours.
  • PATIENTS AND METHODS: In all, 50 patients underwent white-light and NBI cystoscopy to evaluate for recurrent bladder tumours.
  • Endoscopic images in each patient were independently viewed by four urologists assessing presence or absence of tumour.
  • RESULTS: In all, 26 patients had recurrent tumour and 24 had benign histology.
  • There were no significant differences among urologists detecting recurrent tumour or in determining final pathology.
  • CONCLUSIONS: There does not appear to be a 'learning curve' for adapting to NBI-surveillance cystoscopy in patients with bladder cancer.
  • [MeSH-major] Cystoscopy / methods. Image Enhancement / methods. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2008 Nov;102(9):1111-4 [18778359.001]
  • [Cites] BJU Int. 2008 Mar;101(6):702-5; discussion 705-6 [18005206.001]
  • (PMID = 20002669.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088; United States / NCI NIH HHS / CA / T32 CA082088-12
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS297487; NLM/ PMC3137239
  •  go-up   go-down


32. Tiwari P, Tripathi A, Vijay M, Mitra B, Kumar S, Pal DK, Kundu AK: Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience. Indian J Cancer; 2010 Oct-Dec;47(4):418-23
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of the urinary bladder: Rigorous surveillance needed? An Indian experience.
  • AIMS: Inverted papilloma (IP) is an uncommon benign neoplasm of the urinary tract.
  • In this study, we review all cases of urinary bladder IP in our institution and determine the need for strict follow-up.
  • MATERIALS AND METHODS: We included consecutive patients from August 2004 to August 2008 with IP of the urinary bladder in this study who did not have prior or concurrent urothelial carcinoma.
  • No patient had a synchronous or previous bladder tumor.
  • All were solitary tumors except one, most commonly found at the bladder neck and trigone.
  • CONCLUSIONS: We conclude that when diagnosed by strictly defined criteria, IP as benign urothelial neoplasm was with extremely low incidence of recurrence and good prognosis.
  • It does not seem to be a risk factor for TCC, especially if located in the bladder.
  • [MeSH-major] Papilloma, Inverted / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131756.001).
  • [ISSN] 1998-4774
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


33. Jarmalaite S, Jankevicius F, Kurgonaite K, Suziedelis K, Mutanen P, Husgafvel-Pursiainen K: Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer. Oncology; 2008;75(3-4):145-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
  • AIMS: Superficial bladder cancer is a highly recurrent disease, with progression to muscle invasiveness occurring in 15-30% of cases.
  • Promoter hypermethylation in a panel of tumour suppressor genes involved in cell cycle control, apoptosis and DNA repair was analyzed in superficial bladder tumours in order to evaluate the suitability of epigenetic biomarkers for an earlier prediction of the aggressive course of the disease.
  • METHOD: Promoter hypermethylation in p16, RARbeta, RASSF1A, DAPK, and MGMT genes was analyzed in 58 cases with superficial bladder cancer and 2 cases with benign urological disease using methylation-specific PCR.
  • RESULTS: Promoter hypermethylation was frequently detected in RARbeta, RASSF1A and DAPK genes, and 62% of bladder tumours exhibited hypermethylation in at least one gene.
  • The overall frequency of hypermethylation and the number of genes involved increased with tumour stage, grade and muscle invasiveness.
  • Aberrant methylation of RASSF1A and RARbetawas predominant (p < 0.05) in muscle-invasive tumours and high-grade tumours, respectively.
  • CONCLUSION: The results suggest analysis of promoter hypermethylation as a valuable biomarker for prognosis of the aggressive course of disease in bladder cancer.
  • [MeSH-major] DNA Methylation. Genes, Tumor Suppressor. Promoter Regions, Genetic / genetics. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. DNA, Neoplasm / genetics. Female. Humans. Male. Middle Aged. Muscle Neoplasms / genetics. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Staging. Polymerase Chain Reaction. Prognosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18824877.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


34. Sun Y, He DL, Ma Q, Wan XY, Zhu GD, Li L, Luo Y, He H, Yang L: Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Engl); 2006 Nov 5;119(21):1763-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of seven screening methods in the diagnosis of bladder cancer.
  • BACKGROUND: We compared the validity (evaluated by sensitivity and specificity), reliability (evaluated by reproducibility) and yield (evaluated by predictive value, examining complexity and cost) of individual and combined tests for bladder tumour antigen stat (BTAstat), nuclear matrix protein 22 (NMP22), hyaluronic acid (HA), survivin, CD44v6, vascular endothelial growth factor (VEGF), and voided urine cytology (VUC) in detecting bladder cancer.
  • And at the same time we evaluated the clinical value of these seven detecting methods in the diagnosis of bladder cancer.
  • METHODS: The six markers and VUC were detected in the urine of cancer group (151 patients with bladder cancer) and two control groups (50 patients with benign urological diseases and 50 healthy controls).
  • RESULTS: There was a significant difference between bladder cancer group and the two control groups.
  • CONCLUSIONS: All the markers have obvious clinical value in diagnosis of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD44 / analysis. Antigens, Neoplasm / analysis. Female. Glycoproteins / analysis. Humans. Hyaluronic Acid / analysis. Inhibitor of Apoptosis Proteins. Male. Microtubule-Associated Proteins / analysis. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Nuclear Proteins / analysis. Sensitivity and Specificity. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097029.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


35. Kang JU, Koo SH, Jeong TE, Kwon KC, Park JW, Jeon CH: Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma. Cancer Genet Cytogenet; 2006 Jan 1;164(1):32-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multitarget fluorescence in situ hybridization and melanoma antigen genes analysis in primary bladder carcinoma.
  • Conventional urine cytology has a poor prognostic performance for detecting bladder cancer, particularly for low-grade tumors.
  • Fluorescence in situ hybridization (FISH) for chromosomes altered in bladder cancer and testing for antigens selectively expressed in tumors are promising alternatives.
  • This study investigated the use of FISH for detecting aneuploidy of chromosomes 3, 7, 17, and 9p21 and reverse transcriptase PCR (RT-PCR) for the expression of melanoma associated antigen (MAGE) genes for the diagnosis of bladder cancer in voided urine specimens.
  • The two techniques were compared with cystoscopic bladder biopsy results in 47 patients with urothelial cancer and 15 patients with benign prostatic hyperplasia.
  • The sensitivity of FISH increased with histologic grade and stage of the tumors, correctly identifying 77.8% of pTa and pTis, 94.1% of pT1, and 100% of Pt2-4 tumors.
  • MAGE, however, showed a decreased sensitivity in high grade advanced tumors; it was positive in 66.7% of pTa and pTis, 70.6% of pT1, and 50% of Pt2-4 tumors.
  • Combined FISH and MAGE RT-PCR testing may offer a promising alternative to conventional urine cytology in screening high-risk populations and in monitoring bladder cancer patients for recurrent tumor.
  • [MeSH-major] In Situ Hybridization, Fluorescence. Neoplasm Proteins / genetics. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm. Female. Humans. Male. Melanoma-Specific Antigens. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364760.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


36. Inamoto T, Shah JB, Kamat AM: Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol; 2009 Nov-Dec;27(6):585-91
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
  • The peroxisome proliferator-activated receptor (PPAR) family is an important group of transcription factors that regulates immune surveillance, cell proliferation, fatty acid regulation, and angiogenesis--functions which have all been implicated in the pathogenesis of bladder cancer.
  • One particular subtype, PPARgamma, is expressed at higher levels in bladder cancer specimens than in benign urothelium, and is an attractive molecular target for the development of novel treatment strategies for bladder cancer.
  • In this review, we summarize the data available regarding relevance of PPARgamma in bladder cancer and discuss the potential value of PPAR-targeted treatment of bladder cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. PPAR gamma / agonists. PPAR gamma / metabolism. Thiazolidinediones / therapeutic use. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adjuvants, Immunologic / administration & dosage. Adjuvants, Immunologic / therapeutic use. Animals. Apoptosis / drug effects. BCG Vaccine / administration & dosage. BCG Vaccine / therapeutic use. Disease Progression. Humans. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162510.001).
  • [ISSN] 1873-2496
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / BCG Vaccine; 0 / PPAR gamma; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone
  • [Number-of-references] 72
  •  go-up   go-down


37. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol; 2010 Dec;27(4):1286-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
  • Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity.
  • The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer.
  • This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers.
  • Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin.
  • Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Fibronectins / urine. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Case-Control Studies. Cystoscopy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. ROC Curve. Schistosoma mansoni / pathogenicity. Schistosomiasis / diagnosis. Schistosomiasis / genetics. Schistosomiasis / urine. Sensitivity and Specificity. Survival Rate. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012564.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


38. Husillos Alonso A, Subirá Ríos D, Molina Escudero R, Hernández Fernández C: Villous adenoma in augmentation colocystoplasty asociated to infiltrating urotelial cancer in bladder remanent. Arch Esp Urol; 2010 Dec;63(10):876-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma in augmentation colocystoplasty asociated to infiltrating urotelial cancer in bladder remanent.
  • RESULTS: We report the case of a 66 year-old man with a villous adenoma and synchronic infiltrating transitional cell carcinoma of the bladder after augmentation colocystoplasty.
  • CONCLUSIONS: Villous adenoma is a benign neoplasm that occurs in the colonic mucosa and shows a high ability to become a malignant colonic cancer.
  • [MeSH-major] Adenoma, Villous / etiology. Carcinoma, Transitional Cell / etiology. Neoplasms, Multiple Primary / etiology. Urinary Bladder Neoplasms / etiology. Urinary Reservoirs, Continent / adverse effects

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187572.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


39. Zhou M, Reuther AM, Levin HS, Falzarano SM, Kodjoe E, Myles J, Klein E, Magi-Galluzzi C: Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor. Mod Pathol; 2009 Mar;22(3):385-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic bladder neck involvement by prostate carcinoma in radical prostatectomy specimens is not a significant independent prognostic factor.
  • The independent prognostic importance of microscopic bladder neck involvement by prostate cancer in radical prostatectomy is questionable.
  • We studied a cohort of 1845 patients to determine the significance of microscopic bladder neck involvement.
  • Bladder neck involvement was defined as prostate cancer present within the coned bladder neck.
  • We further categorized the cases as 'true bladder neck involvement' and 'false bladder neck involvement.
  • ' True bladder neck involvement required prostate cancer within thick smooth muscle bundles without intermixed benign prostatic glands.
  • False bladder neck involvement was characterized by prostate cancer intermixed with benign prostatic glands.
  • Bladder neck involvement was analyzed in relation to preoperative serum prostate-specific antigen (PSA) level, extraprostatic extension, seminal vesicle involvement, positive surgical margin, lymph node involvement, radical prostatectomy Gleason score, and tumor volume.
  • Of the 90 patients (4.9%) with microscopic bladder neck involvement, 63 were further classified as true bladder neck involvement and 27 as false bladder neck involvement.
  • In univariate model, both types of bladder neck involvement (P<0.001), true (P<0.001), and false (P=0.040), were significantly associated with increased PSA-recurrence risk compared to bladder neck negative cases.
  • In multivariate model the PSA-recurrence relative risk associated with bladder neck involvement (true or false) was not a significant independent prognostic factor.
  • The time to biochemical recurrence in patients with bladder neck involvement was similar to that of pT2 with positive surgical margin or pT3a with negative surgical margin patients (Kaplan-Meier curves).
  • Bladder neck involvement was associated with other adverse pathologic features, but was not an independent predictor of PSA recurrence.
  • In view of the previous and current data, the staging system for bladder neck involvement should be revised and patients may be best categorized as having pT3a disease.
  • [MeSH-major] Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19043400.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


40. Tal R, Sivan B, Kedar D, Baniel J: Management of benign ureteral strictures following radical cystectomy and urinary diversion for bladder cancer. J Urol; 2007 Aug;178(2):538-42
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of benign ureteral strictures following radical cystectomy and urinary diversion for bladder cancer.
  • PURPOSE: Ureteral obstruction due to benign strictures is a significant complication of radical cystectomy and urinary diversion for bladder cancer that can lead to renal function loss and infection related morbidity.
  • We describe the 10-year experience at our department with various treatment modalities for post-cystectomy benign strictures.
  • MATERIALS AND METHODS: The study group consisted of 28 patients treated for benign ureteral strictures following radical cystectomy for bladder cancer.
  • RESULTS: The study group represented 12.7% of all 221 patients treated at our department with radical cystectomy for bladder cancer in 1994 to 2004.
  • Median time to diagnosis was 7.0 months and 75% of the patients were diagnosed within year 1 after cystectomy.
  • CONCLUSIONS: Benign ureteral strictures commonly occur during postoperative year 1 and they are usually asymptomatic.
  • Early diagnosis and prompt drainage are required to prevent consequent renal parenchymal loss and infectious complications.
  • [MeSH-major] Cystectomy. Postoperative Complications / therapy. Ureteral Obstruction / surgery. Urinary Bladder Neoplasms / surgery. Urinary Diversion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Catheterization. Diagnostic Imaging. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous. Recurrence. Reoperation. Retrospective Studies. Risk Factors. Stents


41. Naim M: Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature embryoid teratoma of the gall bladder: case of a primary primitive neoplasm.
  • This study presents diagnostic histopathological features of a primary embryoid teratomatous neoplasm in the gall bladder of a 60-year-old woman, and also discusses its pathogenesis.
  • The residual endothelial lining of the gall bladder showed in situ and proliferative changes characteristic of an endodermal tumour.
  • Results show that the mature adult gall bladder is susceptible to primary neoplasms of a primitive nature ranging from immature embryoma and teratoma to neuroectodermal tumour.
  • Such primitive neoplasms in adult organs where benign neuroectodermal elements are present may evolve from a constituent cell of an adult organ acquired during embryogenesis from a morula that differentiated into trophoblastic (outer) and embryoblastic (inner) cells, and existing dormant cells at rest until reactivation during oncogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2003 Apr;16(4):299-308 [12692194.001]
  • [Cites] Br J Surg. 1961 Jul;49:3-8 [14492775.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] J Postgrad Med. 2006 Oct-Dec;52(4):304-5 [17102555.001]
  • [Cites] J Pediatr Surg. 2007 Oct;42(10):E25-7 [17923185.001]
  • (PMID = 21687015.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027538
  •  go-up   go-down


42. Tavora F, Montgomery E, Epstein JI: A series of vascular tumors and tumorlike lesions of the bladder. Am J Surg Pathol; 2008 Aug;32(8):1213-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A series of vascular tumors and tumorlike lesions of the bladder.
  • Vascular tumors of the bladder are rare and a subject of small series and case reports.
  • We retrospectively identified vascular tumors of the urinary bladder from the consultation files from one of the authors.
  • Hematuria was the most common presentation of both benign and malignant lesions.
  • Histologically, benign and malignant lesions were similar to their counterparts in other organ systems.
  • Patients with hemangiomas, papillary endothelial hyperplasias, and AVM had an invariably benign prognosis and needed no further therapy.
  • These benign lesions had consistent involvement of the submucosa and spared the muscularis propria of the organ.
  • The patient with EHE had a single nodule treated by transurethral resection of the bladder and no evidence of disease at 4 years of follow-up.
  • A wide spectrum of benign, intermediate malignant, and malignant vascular lesions primarily involved the bladder.
  • Despite the potential for marked hemorrhage, none of the tumors resulted in marked hematuria.
  • Papillary endothelial hyperplasia occurs in the bladder and must be differentiated from angiosarcoma, which has a rapidly fatal outcome.
  • [MeSH-major] Neoplasms, Vascular Tissue / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arteriovenous Malformations / pathology. Endothelium, Vascular / pathology. Female. Hemangioendothelioma / pathology. Hemangioendothelioma, Epithelioid / pathology. Hemangioma / pathology. Hemangiosarcoma / pathology. Hematuria / etiology. Humans. Hyperplasia. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580491.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Seifert HH, Schmiemann V, Mueller M, Kazimirek M, Onofre F, Neuhausen A, Florl AR, Ackermann R, Boecking A, Schulz WA, Grote HJ: In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp Mol Pathol; 2007 Jun;82(3):292-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer.
  • Global DNA hypomethylation is a common phenomenon in bladder cancer.
  • Therefore we investigated whether it is possible to detect and assess global DNA hypomethylation in bladder cancer using a specific monoclonal antibody for 5-methyl-cytosine.
  • Cytospins from exfoliative urine cytology specimens of patients with bladder cancer or a history of bladder cancer, control patients with benign urological diseases and of young healthy volunteers were analyzed.
  • Lowest 5-methylcytosine immunostaining scores were observed in carcinoma cells and a statistically significant difference was observed between urothelial cells of healthy controls or patients with benign disease compared to bladder cancer patients (p<0.01, p<0.05, respectively).
  • Our results strongly support the hypothesis of early global demethylation in bladder cancer.
  • [MeSH-major] 5-Methylcytosine / metabolism. Cytodiagnosis. DNA Methylation. DNA, Neoplasm / urine. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026997.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / DNA, Neoplasm; 6R795CQT4H / 5-Methylcytosine
  •  go-up   go-down


44. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y: Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res; 2006 Dec 15;12(24):7369-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease.
  • PURPOSE: To determine the association of the cell proliferative marker Ki-67 with pathologic features and disease prognosis in patients with transitional cell carcinoma (TCC) of the urinary bladder.
  • METHODS: Immunohistochemical staining for Ki-67 was done on serial cuts from tissue microarrays containing cystectomy specimens from 9 patients without bladder cancer and 226 consecutive patients with bladder TCC.
  • In contrast, it was absent in all nine benign cystectomy specimens.
  • In multivariate analyses, pathologic stage and lymph node metastases were independent predictors of disease recurrence and bladder cancer-specific mortality.
  • In the subgroup of patients with organ-confined disease (<pT(3) N(0); n = 91), excluding patients who received neoadjuvant or adjuvant chemotherapy, Ki-67 status was an independent predictor of both disease recurrence (risk ratio, 7.591; P = 0.001) and bladder cancer-specific mortality (risk ratio, 4.045; P = 0.041).
  • CONCLUSIONS: Ki-67 overexpression is associated with features of aggressive bladder TCC and adds independent prognostic information to standard pathologic features for prediction of clinical outcome after radical cystectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Ki-67 Antigen / physiology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / physiology. Cystectomy / statistics & numerical data. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189409.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


45. Ahmad Z, Qureshi A: Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Gallstones.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet ring cell carcinoma of gall bladder: report of an extremely rare histological type of primary gall bladder carcinoma.
  • Signet ring cell carcinoma is an extremely rare type of gall bladder carcinoma composed overwhelmingly (90%) of signet ring cells.
  • It is necessary to exclude a gastric or colonic signet ring cell carcinoma secondarily involving the gall bladder.
  • The primary aim of this case report is to describe the histopathological aspects of this tumour.
  • Primary signet ring cell carcinoma of gall bladder shows dysplastic surface gall bladder epithelium with infiltration of gall bladder wall.
  • It is also necessary to exclude benign signet ring change, which sometimes occurs in the gall bladder.
  • This case showed grossly diffuse thickening of the gall bladder wall and dysplastic surface epithelium of the gall bladder on histology, with sheets of signet ring cells infiltrating full thickness of the wall.
  • It is also necessary to exclude benign signet ring cell change, which sometimes occurs in the gall bladder.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Cholelithiasis / diagnosis. Cholelithiasis / surgery. Gallbladder Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Cholecystectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Mucous Membrane / pathology. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pakistan. Rare Diseases. Risk Assessment

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1988 Apr;29(4):315-8 [2832956.001]
  • [Cites] Rom J Morphol Embryol. 1991 Jul-Dec;37(3-4):171-3 [1667605.001]
  • [Cites] Adv Ther. 2008 May;25(5):520-3 [18461291.001]
  • [Cites] Pathol Res Pract. 2001;197(11):785-8 [11770024.001]
  • [Cites] Pathol Res Pract. 1998;194(3):197-200 [9587939.001]
  • [Cites] Australas J Dermatol. 2007 Aug;48(3):187-9 [17680973.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pathol Int. 1997 Jun;47(6):368-76 [9211524.001]
  • (PMID = 22778190.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028283
  •  go-up   go-down


46. Pu XY, Wang ZP, Chen YR, Wu YL, Wang HP, Wang XH: [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer]. Ai Zheng; 2008 Sep;27(9):970-3
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
  • BACKGROUND & OBJECTIVE: Bladder cancer is the most common malignancy of all genitourinary tumors.
  • Urine cytology is the "gold standard" for non-invasive diagnosis of bladder cancer, but its sensitivity is low.
  • This study was to explore the clinical value of combined detection with urinary bladder cancer antigen (UBC), hyaluronic acid (HA) and cytokeratin 20 (CK20) in the diagnosis of bladder cancer.
  • METHODS: Urine samples were obtained from 64 patients with bladder cancer and 20 patients with benign urological disease.
  • RESULTS: UBC, HA and CK20 yielded significantly higher sensitivity in detecting bladder cancer compared to urinary cytology (85.9%, 89.1% and 78.1% vs. 40.6%, P<0.01).
  • The specificity of UBC, HA, CK20 and urinary cytology for the detection of bladder cancer were 85.0%, 80.0%, 80.0% and 95.0%, respectively.
  • The sensitivity of UBC, HA and CK20 were all significantly higher than that of urinary cytology in detecting different histological stages and grades of bladder cancer (P<0.01).
  • The value of UBC had no significant difference in different histological stages and grades of bladder cancer (P>0.05).
  • Combined use of UBC, HA and CK20 improved the sensitivity and specificity of detecting bladder cancer to 96.9% (62/64) and 100.0%, respectively.
  • CONCLUSIONS: Combined use of UBC, HA and CK20 can improve the sensitivity and specificity for the detection of bladder cancer in urine, thus it may replace conventional cystoscopy in the primary diagnosis.
  • [MeSH-major] Antigens, Neoplasm / urine. Carcinoma, Transitional Cell / diagnosis. Hyaluronic Acid / urine. Keratin-20 / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radioimmunoassay. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799038.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-20; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


47. Taylor JA 3rd, Ristau B, Bonnemaison M, Voznesensky OS, Hegde P, Kuchel GA, Pilbeam CC: Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice. Prostaglandins Other Lipid Mediat; 2009 Jan;88(1-2):36-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice.
  • Prostaglandin E(2) (PGE(2)) is reported to play an important role in tumor development.
  • We explored the differential expression of genes governing production of, and response to, PGE(2) during development of invasive bladder cancer.
  • Half of each bladder was analyzed histologically and the other half extracted for mRNA analysis by quantitative real-time PCR.
  • Hence, increased COX-2 and decreased PDGH expression occurred throughout tumor development, while mPGES-1, EP2R and EP4R were elevated only before development of invasive cancer.
  • We compared expression of these genes in the malignant human urothelial cell lines, HTB-5 and HT-1376, with expression in a benign urothelial cell line, UROtsa.
  • Neither malignant cell line reproduced the complete in vivo pattern, relative to benign cells, but each showed abnormal basal expression of several of the genes downstream of COX-2, but not COX-2 itself.
  • We conclude that components involved in PGE(2) synthesis and activity are differentially regulated during bladder tumor development and the therapeutic efficacy of targeting the various components may vary with stage of tumor development.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5599-602 [11059745.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Urol Res. 2001 Feb;29(1):20-4 [11310210.001]
  • [Cites] J Bone Miner Res. 2002 Aug;17(8):1430-40 [12162497.001]
  • [Cites] J Urol. 2003 Mar;169(3):938-42 [12576817.001]
  • [Cites] Regul Pept. 2003 Jul 15;114(2-3):101-7 [12832097.001]
  • [Cites] J Urol. 2003 Sep;170(3):985-9 [12913755.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):266-70 [12954496.001]
  • [Cites] Eur Urol. 2003 Oct;44(4):435-41 [14499677.001]
  • [Cites] J Cell Mol Med. 2003 Jul-Sep;7(3):207-22 [14594546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Urology. 2004 Oct;64(4):637-42 [15491687.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):33-6 [8476227.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] J Clin Invest. 1997 Sep 15;100(6):1325-9 [9294096.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer Lett. 2005 Jan 10;217(1):11-6 [15596291.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3217-23 [15542609.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2424-30 [10873095.001]
  • [Cites] Urology. 2000 Oct 1;56(4):671-6 [11018637.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] J Intern Med. 2005 Aug;258(2):115-23 [16018788.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):713-25 [16110317.001]
  • [Cites] Gut. 2006 Jan;55(1):115-22 [16118353.001]
  • [Cites] Clin Genitourin Cancer. 2005 Dec;4(3):203-11 [16425990.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3106-13 [16540660.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 May;74(5):309-15 [16621493.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6649-56 [16818638.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9794-7 [17047037.001]
  • [Cites] J Urol. 2007 Mar;177(3):1163-8 [17296438.001]
  • [Cites] Exp Dermatol. 2007 May;16(5):445-53 [17437488.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2007 May;83(3):203-8 [17481556.001]
  • [Cites] BMC Cancer. 2007;7:135 [17650334.001]
  • [Cites] Carcinogenesis. 1999 Dec;20(12):2305-10 [10590224.001]
  • [Cites] J Clin Invest. 2000 Mar;105(6):823-32 [10727451.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):471-7 [16391871.001]
  • (PMID = 18834948.001).
  • [ISSN] 1098-8823
  • [Journal-full-title] Prostaglandins & other lipid mediators
  • [ISO-abbreviation] Prostaglandins Other Lipid Mediat.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK048361; United States / NIDDK NIH HHS / DK / DK048361-08; United States / NIA NIH HHS / AG / R01AG028657; United States / NIDDK NIH HHS / DK / R01 DK048361-08; United States / NIA NIH HHS / AG / AG028657-02; United States / NIDDK NIH HHS / DK / DK048361-13; United States / NIA NIH HHS / AG / R01 AG028657; United States / NIA NIH HHS / AG / R01 AG028657-02; United States / NIDDK NIH HHS / DK / R01DK48361; United States / NIDDK NIH HHS / DK / R01 DK048361-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prostaglandins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS84408; NLM/ PMC2615552
  •  go-up   go-down


48. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y: Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol; 2007 Mar;177(3):1163-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
  • PURPOSE: We compared the differential expression of cyclooxygenase-2 in normal bladder tissue, primary bladder transitional cell carcinoma and transitional cell carcinoma metastases to lymph nodes, and determined whether cyclooxygenase-2 expression is associated with molecular alterations commonly found in bladder transitional cell carcinoma and clinical outcomes after radical cystectomy.
  • MATERIALS AND METHODS: Immunohistochemical staining for cyclooxygenase-2, survivin (Novus Biologicals, Littleton, Colorado), p21, p27, pRB, p53, MIB-1, Bax, Bcl-2, cyclin D(1) (Dakotrade mark), cyclin E (Oncogene, Cambridge, Massachusetts) and caspase-3 (Cell Signaling, Beverley, Massachusetts) was performed on archival bladder specimens from 9 subjects who underwent cystectomy for benign causes, 21 patients who underwent transurethral resection and 157 consecutive patients after radical cystectomy, and on 41 positive lymph nodes.
  • RESULTS: Cyclooxygenase-2 was expressed in none of the 9 normal bladder specimens (0%), 52% of transurethral resection specimens, 62% of cystectomy specimens and 80% of lymph nodes involved with transitional cell carcinoma.
  • On univariate analysis cyclooxygenase-2 expression was associated with an increased risk of disease recurrence and bladder cancer specific mortality (p=0.0189 and 0.0472, respectively).
  • CONCLUSIONS: Cyclooxygenase-2 is not expressed in normal bladder urothelium.
  • Cyclooxygenase-2 over expression is associated with pathological and molecular features of biologically aggressive disease, suggesting a role for cyclooxygenase-2 in bladder cancer development and invasion.
  • [MeSH-major] Carcinoma, Transitional Cell / enzymology. Cyclooxygenase 2 / metabolism. Urinary Bladder Neoplasms / enzymology. Urothelium / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / metabolism. Case-Control Studies. Cell Cycle Proteins / metabolism. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging


49. Niu ZB, Yang Y, Hou Y, Chen H, Liu X, Wang CL: Lymphangioma of bladder. Urology; 2010 Oct;76(4):955-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphangioma of bladder.
  • Lymphangioma in the bladder is extremely rare.
  • Ultrasonography, computed tomogram, and retrograde urethrography showed a mass that was in the wall of the bladder.
  • The tumor was red and found to be bulging into the bladder on the right lateral wall of the bladder by cystoscopy.
  • A partial cystectomy was performed and histology revealed a lymphangioma of the bladder.
  • This case, to the authors' knowledge, represents the third reported case of lymphangioma of bladder.Lymphangiomas are benign, soft-tissue tumors of lymphatic origin.
  • They rarely affect the urinary system and a location in the bladder is extremely rare.
  • Only 2 cases of lymphangioma of the bladder have been reported worldwide since 1983.
  • The present report describes a patient with a lymphangioma of the bladder and the imaging characteristics of the lesion are reported, including imagings of sonography, computed tomography, retrograde urethrography, and histologic examination.
  • [MeSH-major] Lymphangioma / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20494412.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


50. Shi B, Laudon V, Yu S, Dong D, Zhu Y, Xu Z: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int; 2008;81(3):320-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
  • OBJECTIVE: To investigate the clinical significance of E-cadherin (E-CD) expression in human bladder transitional cell carcinoma (TCC) tissue and soluble forms of E-cadherin (sE-CD) in the urine of patients with TCC.
  • MATERIALS AND METHODS: One hundred and two specimens of bladder TCC and 10 normal bladder tissues were stained immunohistochemically with anti-E-CD monoclonal antibody.
  • The urinary sE-CD from 59 subjects with TCC or controls was measured with enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The expression of E-CD in bladder TCC correlated well with grade and stage but had no significant correlation with the size or number of the tumors.
  • Normal expression rate of E-CD is significantly higher in primary than in recurrent tumors.
  • The level of urinary sE-CD was higher in patients with TCC than in normal controls or patients with benign disorders of the urinary system.
  • Urinary sE-CD levels were strongly correlated with tumor grade but showed no significant correlation with the stage, size and number of the tumors.
  • The urinary sE-CD level is significantly higher in the recurrent group than in the primary group.
  • CONCLUSIONS: Expression of E-CD in the tissue of TCC and the urinary level of sE-CD are very closely associated with the biological behaviors of bladder TCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Transitional Cell / chemistry. Urinary Bladder Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 18931551.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


51. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM: Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst; 2005 Sep;17(3):193-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
  • PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology.
  • SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group.
  • The levels of the three parameters were significantly higher in the malignant group compared to either the benign group or normal controls, (p<0.001) and the positive rates were also higher in the malignant group for all 3 parameters.
  • For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%.
  • CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%).
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nuclear Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / urine. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / urine. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / urine. Female. Humans. Male. Middle Aged. Schistosomiasis haematobia / complications

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799657.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


52. Shirodkar SP, Lokeshwar VB: Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? Expert Rev Anticancer Ther; 2008 Jul;8(7):1111-23
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?
  • Bladder cancer is a common malignancy in the USA.
  • Currently, the detection of initial tumors and recurrent disease is based on evaluation of voided urinary specimens, often followed by cystoscopy.
  • As a result, intense work is being done in the field of bladder tumor markers with the goal of identifying bladder cancer earlier, both in the initial diagnosis and in recurrences of known tumor.
  • The possibility of identifying a marker that could noninvasively differentiate benign and malignant causes of hematuria, and identify recurrences prior to their pathologic progression is the objective of this area of research.
  • Currently, a large number of tumor markers exist, each scrutinized in both the laboratory and in clinical trials.
  • Some novel modalities for tumor detection are also presented.
  • [MeSH-major] Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Hematuria / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, Neoplasm / urine. Cystoscopy. Humans. Molecular Diagnostic Techniques / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2007;13(3):187-94 [17922047.001]
  • [Cites] J Urol. 2007 Jan;177(1):80-3 [17162008.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):53-61 [10696245.001]
  • [Cites] Int J Oncol. 1993 Oct;3(4):559-63 [21573400.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2000 Nov 1;56(5):793-7 [11068304.001]
  • [Cites] Lancet. 1993 Aug 21;342(8869):469-71 [8102431.001]
  • [Cites] Eur Urol. 1999 Jan;35(1):52-6 [9933795.001]
  • [Cites] World J Urol. 2008 Feb;26(1):59-65 [17962949.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):61-72 [12115318.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):884-94 [7666477.001]
  • [Cites] Cancer Pract. 2002 Nov-Dec;10(6):311-22 [12406054.001]
  • [Cites] Int Surg. 1991 Jan-Mar;76(1):52-4 [2045253.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):810-6 [15713770.001]
  • [Cites] J Urol. 2007 Apr;177(4):1277-82; discussion 1282 [17382711.001]
  • [Cites] Urol Oncol. 2006 Nov-Dec;24(6):528-37 [17138134.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):817-24 [15257544.001]
  • [Cites] J Urol. 2003 Jan;169(1):86-9 [12478110.001]
  • [Cites] J Urol. 2007 Feb;177(2):437-43 [17222605.001]
  • [Cites] Urology. 2001 Apr;57(4):680-4 [11306380.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):699-703 [8976763.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2173-9 [17029275.001]
  • [Cites] Int J Cancer. 2002 Sep 20;101(3):293-7 [12209982.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2511-20 [9796985.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] J Urol. 2001 Aug;166(2):470-5 [11458049.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Urology. 2000 Aug 1;56(2):228-31 [10925083.001]
  • [Cites] Urology. 2003 Jan;61(1):243-7 [12559316.001]
  • [Cites] World J Urol. 2004 Jun;22(2):145-9 [14991320.001]
  • [Cites] J Urol. 1998 Feb;159(2):394-8 [9649246.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 5;119(21):1763-71 [17097029.001]
  • [Cites] J Urol. 2006 Sep;176(3):919-26; discussion 926 [16890655.001]
  • [Cites] World J Urol. 2006 Sep;24(4):418-22 [16688457.001]
  • [Cites] J Urol. 2002 Nov;168(5):1950-4 [12394683.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2001 Oct;166(4):1280-5 [11547058.001]
  • [Cites] J Urol. 1999 Jul;162(1):53-7 [10379739.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):405-9 [17611663.001]
  • [Cites] J Urol. 2006 Jun;175(6):2032-7; discussion 2037 [16697794.001]
  • [Cites] J Urol. 2002 Jan;167(1):80-3 [11743280.001]
  • [Cites] World J Urol. 2008 Feb;26(1):45-50 [18180926.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):25-33; discussion 33-4 [16530072.001]
  • [Cites] Curr Opin Genet Dev. 1991 Dec;1(4):538-43 [1822287.001]
  • [Cites] Semin Diagn Pathol. 1997 May;14(2):123-32 [9179973.001]
  • [Cites] Can J Urol. 1997 Sep;4(3):400-405 [12735818.001]
  • [Cites] Urology. 1998 Nov;52(5):793-6 [9801101.001]
  • [Cites] Med Sci Monit. 2003 Apr;9(4):PI25-9 [12709681.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5352-8 [18048815.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4464-70 [10485499.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Jun;134(6):659-65 [18026991.001]
  • [Cites] Urology. 2004 Feb;63(2):392-7 [14972509.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1356-62 [15717321.001]
  • [Cites] BJU Int. 2006 Nov;98(5):1090-3 [17034609.001]
  • [Cites] BJU Int. 2005 Dec;96(9):1280-5 [16287445.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):171-9 [11801555.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):100-4 [15761870.001]
  • [Cites] J Urol. 2000 Jan;163(1):348-56 [10604388.001]
  • [Cites] J Urol. 1996 Oct;156(4):1280-5 [8808854.001]
  • [Cites] Front Biosci. 2002 Jan 01;7:e27-32 [11779714.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Int J Cancer. 2001 Oct 1;94(1):67-72 [11668480.001]
  • [Cites] ScientificWorldJournal. 2006 Mar 27;6:2617-25 [17619739.001]
  • [Cites] Semin Cancer Biol. 1996 Feb;7(1):15-24 [8695762.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Ann Clin Lab Sci. 2006 Winter;36(1):31-8 [16501234.001]
  • [Cites] Am Fam Physician. 2001 Mar 15;63(6):1145-54 [11277551.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):588-97 [12697851.001]
  • [Cites] Asian J Androl. 2007 Sep;9(5):711-5 [17712491.001]
  • [Cites] Lab Invest. 2003 Jun;83(6):845-52 [12808119.001]
  • [Cites] BJU Int. 2008 Jan;101(1):26-9 [17850364.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):83-9 [15389253.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2):75-84 [17382791.001]
  • [Cites] BJU Int. 2007 Feb;99(2):281-5 [17155984.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Mar;173(2):131-5 [17321328.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • [Cites] Urology. 2003 Nov;62(5):952-7 [14624933.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):274-80 [15900578.001]
  • [Cites] Urol Int. 2001;66(4):185-90 [11385303.001]
  • [Cites] J Natl Cancer Inst. 1997 May 21;89(10):724-30 [9168188.001]
  • [Cites] Eur Urol. 1990;17(4):281-5 [2364965.001]
  • [Cites] Nat Med. 1997 Jun;3(6):621-4 [9176487.001]
  • [Cites] Urol Oncol. 2001 Jul;6(4):163-169 [11418323.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1106-13 [17311310.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):295-301 [17210520.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14 [11894002.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 1):1068-72 [17644139.001]
  • [Cites] Urology. 2001 Sep;58(3):367-71 [11549482.001]
  • [Cites] World J Urol. 2007 Dec;25(6):563-71 [17710407.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] World J Urol. 2000 Dec;18(6):401-5 [11204258.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2618-25 [10914702.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1384-91 [14977841.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2914-22 [12115379.001]
  • [Cites] Urology. 2007 Sep;70(3):482-6 [17905101.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Urology. 2007 Sep;70(3):449-53 [17688921.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1321-6 [16596205.001]
  • [Cites] Urol Clin North Am. 1998 Nov;25(4):661-76 [10026773.001]
  • [Cites] World J Urol. 2008 Feb;26(1):31-7 [18075743.001]
  • [Cites] Blood. 1995 May 1;85(9):2315-20 [7727765.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):329-38 [17373664.001]
  • [Cites] Pharmacoeconomics. 2003;21(18):1315-30 [14750899.001]
  • [Cites] Urology. 2000 Feb;55(2):223-6 [10688083.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):25-37 [10696242.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):951-6; discussion 956 [16257108.001]
  • [Cites] JAMA. 2005 Oct 26;294(16):2052-6 [16249419.001]
  • [Cites] Indian J Med Sci. 2005 Jun;59(6):235-42 [15988093.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):352-7 [17762630.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1388-96 [17466450.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5519-27 [17158537.001]
  • [Cites] Curr Opin Urol. 2008 Jan;18(1):1-8 [18090481.001]
  • [Cites] J Urol. 2007 Jul;178(1):57-61 [17574060.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):678-86 [16129368.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2333-40 [10873084.001]
  • [Cites] Isr Med Assoc J. 2002 Mar;4(3):174-5 [11908255.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1423-7 [3304614.001]
  • [Cites] Med Clin North Am. 2004 Mar;88(2):329-43 [15049581.001]
  • [Cites] Int J Urol. 2007 Feb;14(2):108-11 [17302565.001]
  • [Cites] Br J Urol. 1991 Sep;68(3):248-53 [1717095.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Med Sci Monit. 2003 Aug;9 Suppl 3:25-8 [15156607.001]
  • [Cites] Urology. 2004 Dec;64(6):1121-6 [15596183.001]
  • [Cites] J Urol. 1999 Feb;161(2):443-6 [9915422.001]
  • [Cites] J Urol. 2007 Feb;177(2):481-7; discussion 487 [17222615.001]
  • [Cites] Urology. 1989 Feb;33(2):89-96 [2916296.001]
  • [Cites] Tumour Biol. 2007;28(2):57-62 [17259754.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • (PMID = 18588456.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA072821; United States / NCI NIH HHS / CA / 5R01 CA-72821-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 136
  •  go-up   go-down


53. Haylen BT: The empty bladder. Int Urogynecol J Pelvic Floor Dysfunct; 2007 Mar;18(3):237-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The empty bladder.
  • The empty (near-empty) bladder can have a volume ranging from 0 to 30 ml.
  • Its diagnosis is effectively and least invasively made by ultrasound (transvaginal superior).
  • It is a key marker of normal bladder function.
  • It is necessary for the accurate assessment of uterovaginal prolapse, as increasing bladder volume has been shown to reduce the extent of the prolapse.
  • Any negative effect of prolapse on voiding is reduced at high bladder volumes compared to voiding from low bladder volumes (due to the same reduction in the extent of the prolapse).
  • An empty bladder is optimal for bimanual pelvic examination and most transvaginal ultrasound examinations including that for uterine version.
  • The woman whose bladder is empty post-voiding is at a significantly lower risk of recurrent urinary tract infections.
  • The bladder that can't be emptied is a marker of bladder dysfunction, requiring a fuller investigation.
  • From a surgical point of view, the empty bladder improves access and reduces surgical risks with laparotomy, as well as both laparoscopic and vaginal surgery.
  • [MeSH-major] Urinary Bladder / physiology
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Recurrence. Urinary Tract Infections / physiopathology. Urination / physiology. Uterine Prolapse / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurourol Urodyn. 2000;19(3):213-20 [10797578.001]
  • [Cites] Urology. 2003 Jan;61(1):37-49 [12559262.001]
  • [Cites] Br J Urol. 1989 Jul;64(1):30-8 [2765766.001]
  • [Cites] Br J Urol. 1989 Feb;63(2):149-51 [2649196.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10(6):378-83 [10614974.001]
  • [Cites] Am J Obstet Gynecol. 1996 Jul;175(1):10-7 [8694033.001]
  • [Cites] Radiology. 1991 Apr;179(1):25-33 [2006286.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 1999;10 (1):3-6 [10207759.001]
  • [Cites] Br J Urol. 1966 Apr;38(2):156-62 [5934769.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 May-Jun;16(3):236-41 [15875241.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2006 Nov;17 (6):555-8 [16341460.001]
  • [Cites] Br J Urol. 1989 Feb;63(2):152-4 [2702400.001]
  • [Cites] Radiol Clin North Am. 1992 Sep;30(5):955-76 [1518939.001]
  • [Cites] Br J Urol. 1989 Oct;64(4):350-2 [2684334.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(5):296-300 [11052565.001]
  • (PMID = 16791705.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Lee SH, Mah SY, Chung BH: Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms. J Endourol; 2010 Feb;24(2):271-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidentally discovered inverted papilloma of the urinary bladder in patients with lower urinary tract symptoms.
  • BACKGROUND AND PURPOSE: Inverted urothelial papilloma (IP) is an uncommon urothelial neoplasm.
  • We aimed to determine the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and lower urinary tract symptoms (LUTS).
  • PATIENTS AND METHODS: From 1994 to 2008, 53 patients with urinary IP underwent transurethral resection of the bladder tumor (TURBT) at our institution.
  • We reviewed the clinicopathologic characteristics of IP of the bladder and its association with prostate volume and LUTS.
  • In IP located on the bladder neck of patients with benign prostatic hyperplasia (BPH), significantly higher obstructive symptoms and larger prostate volumes than that of other located IP with BPH were observed.
  • CONCLUSIONS: This is the largest series of cases of urinary bladder IP reported from Korea.
  • Despite the absence of agreement of its etiology, its presenting symptoms were related to LUTS and benign prostatic enlargement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039831.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Bivalacqua TJ, Loeb S, Pierorazio PM, Schoenberg MP, Partin AW, Guzzo TJ: Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer? Urol Int; 2010;85(4):466-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is prostate-specific antigen surveillance necessary in men with benign prostate pathology following radical cystoprostatectomy for bladder cancer?
  • BACKGROUND: Radical cystoprostatectomy (RCP) remains the gold standard for the treatment of muscle-invasive bladder cancer.
  • There are limited data regarding the clinical impact and detection of PSA following complete prostatectomy or the need to monitor serum PSA in patients with benign prostate pathology at time of RCP.
  • The purpose of our study was to analyze the postoperative PSA characteristics of men without prostate cancer who underwent a RCP for bladder cancer.
  • METHODS: The demographic, clinical and pathologic data were reviewed on 138 men who underwent RCP for bladder cancer from 1994 to 2008.
  • CONCLUSIONS: Serum PSA should remain undetectable for men with benign prostate pathology undergoing complete prostatectomy at the time of RCP.
  • Elevated serum PSA following complete RCP in men with bladder cancer and pathologically confirmed benign prostate findings is rare.
  • If the serum PSA is undetectable 3 months after RCP with benign prostate pathology, there is no need for continued PSA monitoring.
  • [MeSH-major] Cystectomy. Prostate / surgery. Prostate-Specific Antigen / blood. Prostatectomy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Baltimore. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Time Factors. Treatment Outcome


56. Siatelis A, Konstantinidis C, Volanis D, Leontara V, Thoma-Tsagli E, Delakas D: Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature. Minerva Urol Nefrol; 2008 Jun;60(2):137-40
MedlinePlus Health Information. consumer health - Pheochromocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pheochromocytoma of the urinary bladder: report of 2 cases and review of literature.
  • Pheochromocytoma of the urinary bladder is a rare neoplasm of the chromaffin tissue of the sympathetic nervous system within the layers of the bladder wall.
  • It accounts for less than 0.06% of all urinary bladder tumors and less than 1% of all pheochromocytomas.
  • The diagnosis is strongly based on the clinical symptoms related to catecholamine hypersecretion.
  • In some cases however, the tumor is hormonally inactive and may go undetected for years.
  • The cytologic features of benign and malignant tumors overlap and thus there are no reliable features of malignancy.
  • Nevertheless the prognosis seems to be better for patients with superficial tumors comparing to patients with invasive tumors, found in 5-10% of cases.
  • For metastatic tumors, chemotherapy and radiotherapy seem to be effective.
  • The authors present two new cases of pheochromocytoma of the urinary bladder.
  • The authors discuss the difficulties in diagnosis and treatment and briefly review literature.
  • [MeSH-major] Pheochromocytoma. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500228.001).
  • [ISSN] 0393-2249
  • [Journal-full-title] Minerva urologica e nefrologica = The Italian journal of urology and nephrology
  • [ISO-abbreviation] Minerva Urol Nefrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 12
  •  go-up   go-down


57. Tamas EF, Epstein JI: Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains. Am J Surg Pathol; 2007 Mar;31(3):390-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
  • Some patients who have had prior bladder biopsies or transurethral resections undergo a repeat resection within several months for various reasons.
  • The detection of a few residual tumor cells in bladder specimens with prior biopsy site changes can be challenging based on histology alone.
  • We have noted several cases in which keratin stains were performed and positive cells were noted, raising the issue as to whether the cytokeratin positive cells were residual tumor cells or stromal cells.
  • Immunohistochemistry for a panel of antibodies [AE1/AE3, CAM 5.2, high molecular weight cytokeratin, smooth muscle actin (SMA), desmin, and anaplastic lymphoma kinase (ALK)] was performed on 29 cases of bladder biopsies with prior biopsy site changes.
  • Of 29 patients, 25 had a prior history of bladder tumor: 17 had invasive high-grade urothelial carcinoma (T1, 5 cases; T2, 11 cases; T3,1 case); 7 had noninvasive high-grade papillary urothelial carcinoma; 1 had noninvasive low-grade papillary urothelial carcinoma).
  • Four patients had prior benign bladder diagnoses: cystitis cystica et glandularis; polypoid cystitis; follicular cystitis; and neurogenic bladder with benign prostate hyperplasia.
  • These cells were interpreted as residual tumors cells.
  • When interpreting CK stains for the detection of residual tumor cells, one should pay attention to the nature of the cells and not assume all CK staining cells are residual tumor cells.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Diagnostic Errors / prevention & control. Keratins / analysis. Neoplasm, Residual / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local. Urothelium / chemistry. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325480.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


58. Karaguzhin SG, Merinov DS, Martov AG: [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia]. Urologiia; 2005 Sep-Oct;(5):17-21
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One-stage transurethral resection of the urinary bladder and the prostate in patients with superficial cancer of the urinary bladder combined with benign prostatic hyperplasia].
  • Combination of urinary bladder cancer (UBC) with benign prostatic hyperplasia (BPH) is a prognostically unfavourable factor.
  • TUR of the urinary bladder and the prostate was made in 87 patients.
  • Stage-by-stage TUR of the urinary bladder and TUR of the prostate were made in 94 controls.
  • Reoperation (TUR of the urinary bladder) was performed in all cases of UBC recurrence.
  • The conclusion is made that in combination of superficial UBC with BPH indications appear for TUR of the urinary bladder and TUR of the prostate with adjuvant immunotherapy.
  • [MeSH-major] Cystectomy. Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder / surgery. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Combined Modality Therapy. Endoscopy. Humans. Immunotherapy. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Treatment Outcome


59. Varkarakis IM, Pinggera G, Antoniou N, Constantinides K, Chrisofos M, Deliveliotis C: Pathological review of internal genitalia after anterior exenteration for bladder cancer in women. Evaluating risk factors for female organ involvement. Int Urol Nephrol; 2007;39(4):1015-21
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological review of internal genitalia after anterior exenteration for bladder cancer in women. Evaluating risk factors for female organ involvement.
  • To evaluate cancer involvement of internal female genitalia of patients undergoing anterior exenteration for clinically organ confined transitional cell carcinoma of the bladder, and identify potential preoperative risk factors.
  • Charts and anterior exenteration specimens from 54 women with clinically organ confined transitional cell bladder cancer were retrospectively reviewed.
  • In all cases involvement was due to direst extension from bladder tumors of the base and dome respectively.
  • Benign pathology of the female reproductive organs was observed in six patients and involved in all cases the uterus (11.5%).
  • Internal genitalia involvement after radical cystectomy for TCC tumors of the bladder is rare (5.8%).
  • Preoperative risk factors could not be identified although all involved genitalia were seen in tumors of the bladder dome and base.
  • Therefore large multi-institutional studies are needed in order to identify preoperative risk factors for internal genitalia involvement in females with bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology. Uterine Neoplasms / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cystectomy. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333520.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


60. Moreira JM, Ohlsson G, Gromov P, Simon R, Sauter G, Celis JE, Gromova I: Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol Cell Proteomics; 2010 Jan;9(1):161-77
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
  • It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors.
  • As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer.
  • Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10.
  • To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up.
  • We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Proteomics / methods. Urinary Bladder Neoplasms / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 16):2891-3 [11686292.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):495-503 [11601134.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):539-46 [11920613.001]
  • [Cites] Neuron. 2002 Apr 25;34(3):349-56 [11988167.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):269-79 [12096109.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3759-64 [12552989.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Science. 2003 Aug 8;301(5634):832-6 [12907802.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):801 [14985749.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):410-9 [14736829.001]
  • [Cites] Pharmacogenomics. 2004 Jun;5(4):381-94 [15165174.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2003 Sep;19(5):465-6 [15169658.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Acta Chir Scand. 1965 Oct;130(4):371-8 [5842510.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;391(2):217-25 [6784337.001]
  • [Cites] Cell. 1991 Oct 4;67(1):11-9 [1717158.001]
  • [Cites] Urol Clin North Am. 1992 Aug;19(3):429-33 [1636228.001]
  • [Cites] Science. 1995 Dec 8;270(5242):1677-80 [7502080.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4782-90 [8840999.001]
  • [Cites] Nature. 1997 May 15;387(6630):303-8 [9153397.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4111-7 [9307301.001]
  • [Cites] Int J Oncol. 1998 Aug;13(2):379-83 [9664136.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):241-8 [10197429.001]
  • [Cites] Electrophoresis. 1999 Feb;20(2):349-54 [10197442.001]
  • [Cites] Hybrid Hybridomics. 2004 Dec;23(6):335-42 [15684659.001]
  • [Cites] Nucleic Acids Res. 2005;33(4):1162-8 [15731336.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):570-81 [15734831.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):1853-8 [15691854.001]
  • [Cites] Bioinformatics. 2005 Jun 1;21(11):2590-5 [15797904.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W226-9 [15980458.001]
  • [Cites] Tumour Biol. 2006;27(4):221-6 [16675915.001]
  • [Cites] Ai Zheng. 2006 Jul;25(7):811-7 [16831269.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1071 [17129789.001]
  • [Cites] Nat Struct Mol Biol. 2007 Mar;14(3):185-93 [17310252.001]
  • [Cites] Mol Cell Biochem. 2007 Mar;297(1-2):81-92 [17031575.001]
  • [Cites] Genome Res. 2007 Nov;17(11):1586-95 [17908822.001]
  • [Cites] J Clin Epidemiol. 2007 Dec;60(12):1205-19 [17998073.001]
  • [Cites] J Biol Chem. 2008 Mar 14;283(11):7251-60 [18178553.001]
  • [Cites] RNA. 2008 Jun;14(6):1110-8 [18430892.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:1-12 [18519955.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):554-6 [18538738.001]
  • [Cites] Urology. 2008 Sep;72(3):706-10 [18342921.001]
  • [Cites] Scand J Urol Nephrol Suppl. 2008 Sep;(218):12-20 [19054893.001]
  • [Cites] Tumour Biol. 2008;29(5):311-22 [18984977.001]
  • [Cites] RNA Biol. 2008 Oct-Dec;5(4):193-7 [18971634.001]
  • [Cites] Mol Oncol. 2007 Dec;1(3):321-49 [19383306.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):384-94 [19383312.001]
  • [Cites] Mol Oncol. 2008 Apr;1(4):406-12 [19383314.001]
  • [Cites] Mol Oncol. 2008 Aug;2(2):153-60 [19383334.001]
  • [Cites] Mol Oncol. 2008 Oct;2(3):213-22 [19383342.001]
  • [Cites] Urol Oncol. 2011 Jan-Feb;29(1):21-6 [19186082.001]
  • [Cites] J Mol Biol. 1999 Dec 17;294(5):1351-62 [10600390.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4079-84 [10632343.001]
  • [Cites] EXS. 2000;88:55-67 [10803371.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):787-94 [10980118.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):726-32 [11072240.001]
  • [Cites] J Mol Biol. 2001 Jan 19;305(3):567-80 [11152613.001]
  • [Cites] J Pathol. 2001 Jul;194(3):349-57 [11439368.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14687-92 [11717408.001]
  • (PMID = 19783793.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BLCAP protein, human; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2808262
  •  go-up   go-down


61. Chen CS, Cheng CL: Nephrogenic adenoma of the urinary bladder: clinical experience and review of the literature. J Chin Med Assoc; 2006 Apr;69(4):166-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma of the urinary bladder: clinical experience and review of the literature.
  • BACKGROUND: Nephrogenic adenoma (NA) is a rare disease of the urinary tract.
  • We report our clinical experience with this disease in the urinary bladder and review the literature.
  • METHODS: Between April 1994 and July 2004, 8 patients were diagnosed with NA of the urinary bladder: 3 men and 5 women, aged 23-77 years (mean 49.6).
  • All patients had recurrent urinary tract infection.
  • Urinary tuberculosis was diagnosed in 2 patients.
  • Previous long-term urinary catheterization was noted in 3 patients.
  • Urinary frequency and microscopic hematuria were found in all patients.
  • Recurrent tumors were also treated with the endourologic method.
  • CONCLUSION: NA is an uncommon benign metaplastic lesion occurring in the urothelium.
  • Transurethral resection of NA provides a definite diagnosis and relief of symptoms.
  • [MeSH-major] Adenoma / etiology. Urinary Bladder Neoplasms / etiology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689198.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


62. Hazzaa SM, Elashry OM, Afifi IK: Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res; 2010 Mar;16(1):101-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder.
  • We investigated the feasibility of profiling and measuring the concentration of clusterin in urine and serum for individuals with transitional cell carcinoma (TCC) of the bladder and comparing it with nontumor controls.
  • In addition, we analyzed the correlation of expression of clusterin in specimens of TCC to various clinicopathologic parameters and prognosis of bladder cancer.
  • Blood and urine samples were used from 68 patients with TCC of the bladder and from 61 patients with benign urological diseases.
  • Quantitation of clusterin mRNA was carried out in 68 bladder tumor specimens from radical cystectomy or transurethral resection and 26 normal bladder specimens from BPH patients by using RT-PCR method.
  • Serum and urine clusterin was significantly higher in individuals with bladder cancer than control (p = 0.001).
  • Sensitivity and specificity of serum and urine clusterin as a tumor marker for TCC of the bladder was found to be 80%, 91%, 87.1% and 96.7% respectively.
  • Expression of clusterin was significantly higher in patients with invasive TCC of the bladder than that in patients with superficial TCC and control (P < 0.001).
  • Overexpression of clusterin mRNA was significantly associated with tumor recurrence and overall survival (p < 0.001).
  • Clusterin may be considered as a potential diagnostic and prognostic biomarker for bladder cancer using urine, serum and/or molecular biology techniques.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Clusterin / biosynthesis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757199.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


63. Juan Escudero JU, Ramos de Campos M, Ordoño Domínguez F, Fabuel Deltoro M, Serrano de la Cruz Torrijos F, Navalón Verdejo P, López Alcina E, Zaragoza Orts J: [Inguinoscrotal bladder hernias]. Arch Esp Urol; 2007 Apr;60(3):231-6
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Inguinoscrotal bladder hernias].
  • In the general population, only a small percentage of them involve the bladder.
  • Bladder wall weakness and bladder outlet obstruction are involved in its pathogenesis.
  • We present our experience in the diagnosis and treatment of this rare disease.
  • METHODS: A total of eight patients have been diagnosed of inguinoscrotal bladder hernia and treated in our center over the last 18 years.
  • In most cases, retrograde and voiding cystourethrograms, prostatic and bladder ultrasound, and uroflowmetry have been performed.
  • The treatment varied depending on the characteristics of the herniated bladder tissues and bladder capacity.
  • The treatment of bladder outlet obstruction varied depending on the etiology.
  • Resection of the herniated bladder tissue was carried out in four patients due to the quality of the tissue; bladder-pexy to the abdominis rectus muscles was performed in one patient; hernia repair with bladder reintroduction was the treatment in the other four cases.
  • Bladder outlet obstruction was treated in six cases.
  • Seven patients showed clinical improvement, showing normal bladder morphology on post operative cystogram.
  • CONCLUSIONS: Bladder hernia is a rare pathology often presenting in mid age males.
  • It should be suspected in every male with lower urinary tract obstructive symptoms and associated inguinal hernia.
  • The treatment of choice is that of the hernia and bladder outlet obstruction.
  • [MeSH-major] Genital Diseases, Male / diagnosis. Genital Diseases, Male / surgery. Hernia, Inguinal / diagnosis. Hernia, Inguinal / surgery. Scrotum. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601297.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


64. Denzinger S, Stoehr R, Schwarz S, Eichenseher N, Brockhoff G, Obermann EC, Knuechel R, Blaszyk H, Hartmann A, Wild PJ: Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy. Int J Oncol; 2007 Oct;31(4):793-802
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low level STK15 amplification in histologically benign urothelium of patients with bladder cancer adversely predicts patient outcome following cystectomy.
  • The aim of this study was to investigate STK15 amplification in histologically benign urothelium and invasive tumor tissue of urothelial bladder cancer patients in relation to clinicopathologic and molecular characteristics, and to analyze a hypothesized association between the STK15 single nucleotide polymorphism at site T91A (Phe31Ile) and STK15 gene amplification.
  • A tissue microarray (TMA) was constructed and contained formalin-fixed paraffin-embedded tumor tissue and matching histologically benign urothelium of 44 patients who underwent cystectomy for invasive urothelial carcinoma.
  • Low level STK15 amplification was found in 2 of 36 analyzable histologically benign urothelium specimens (5.6%) and in 64% (28/44) of urothelial bladder cancers, whereas 36% (16/44) of cancer lesions showed high level of STK15 amplification.
  • In histologically benign urothelium of bladder cancer patients, low level STK15 amplification was associated with shorter recurrence-free and tumor-specific survival.
  • Applying STK15 FISH to benign urothelium of bladder cancer patients may help to identify patients at increased risk for adverse clinical outcome.
  • A large randomized prospective study comparing early versus delayed cystectomy in patients with pT1 bladder cancer is currently conducted to validate our findings.
  • [MeSH-major] Cystectomy. Protein-Serine-Threonine Kinases / genetics. Urinary Bladder Neoplasms / genetics. Urothelium / pathology
  • [MeSH-minor] Aged. Aurora Kinase A. Aurora Kinases. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Case-Control Studies. Chromosome Aberrations. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / surgery. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Precancerous Conditions / pathology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786310.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


65. Babjuk M, Soukup V, Mares J, Dusková J, Pecen L, Pesl M, Pavlík I, DvorRcek J: Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. Urology; 2006 Apr;67(4):756-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder.
  • OBJECTIVES: To assess the frequency and intensity of PAX5 gene messenger ribonucleic acid (mRNA) expression in TaT1 bladder cancer tissue, as well as its correlation with clinicopathologic variables and patient outcome.
  • METHODS: The RNA expression of PAX5 was evaluated with reverse transcriptase polymerase chain reaction in the tumor tissue of 75 patients with stage TaT1 bladder cancer treated with transurethral resection.
  • Patients were observed with cystoscopy and urinary cytologic evaluation.
  • Benign urothelium from 8 patients with benign prostatic hyperplasia was obtained.
  • RESULTS: PAX5 expression was found in 62 patients with bladder cancer (82.7%) but in no patient from the control group.
  • Multivariate Cox proportional hazard model analysis identified PAX5 expression as an independent predictor of tumor recurrence.
  • CONCLUSIONS: PAX5 gene expression is a frequent finding in superficial transitional cell carcinoma of the bladder.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Carcinoma, Transitional Cell / genetics. Gene Expression Regulation, Neoplastic. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566978.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


66. Herawi M, Leppert JT, Thomas GV, De Kernion JB, Epstein JI: Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: support for "seed and soil" hypothesis of bladder recurrence. Urology; 2006 Apr;67(4):746-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implants of noninvasive papillary urothelial carcinoma in peritoneum and ileocolonic neobladder: support for "seed and soil" hypothesis of bladder recurrence.
  • OBJECTIVES: To explore the underlying mechanism of tumor regrowth in cases of noninvasive urothelial carcinoma that recur in unusual anatomic locations.
  • One had presented as an implant in the peritoneal investment of the bladder dome and the other as multiple implants growing on the benign surface of the colonic mucosa of an orthotopic neobladder distant from the anastomosis site.
  • Although the urinary bladder was free of neoplastic changes at nephroureterectomy, both patients also developed several papillary tumors within the bladder shortly after the removal of the kidney.
  • CONCLUSIONS: After clinicopathologic correlation, the mode of tumor spread in these cases was best explained by the "seeding/implantation" theory.
  • The urothelial tumor cells in each of these cases demonstrated the ability to implant themselves not only in the urothelium of the bladder but also in the colonic mucosa of a constructed neobladder and on the peritoneal surface.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Neoplasm Recurrence, Local / etiology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566991.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Blah M, Nouira Y, Kallel Y, Hafsia GH, Horchani A: [Bladder herniation]. Ann Chir; 2005 Dec;130(10):633-5
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder herniation].
  • Inguinal hernia of the bladder is uncommon.
  • The diagnosis is frequently done during surgery.
  • It can be evoked before surgery when the patient presents with irritative and obstructive lower urinary tract symptoms.
  • Retrograde urethrocystography or computerized tomography confirm the diagnosis.
  • We report a case of bilateral inguinal hernia involving the bladder at the right side in a 87 years old man who had a surgical history of transvesical adenomectomy of the prostate.
  • The diagnosis was done on the retrograde urethrocystography.
  • We performed bilateral herniorrhaphy with herniated bladder reduction.
  • [MeSH-major] Hernia, Inguinal / surgery. Urinary Bladder Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16043116.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


68. Jaidane M, Bouicha T, Slama A, Hmida W, Hidoussi A, Ben Sorba N, Mosbah F: Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study. Urology; 2010 Jun;75(6):1392-5
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate: a comparative retrospective study.
  • OBJECTIVES: To evaluate the effect on the oncological outcomes and recurrences at the prostatic urethra of simultaneous transurethral resection of bladder tumor (TURBT) and benign prostatic hyperplasia (TURP).
  • Clinicopathologic parameters, recurrence and progression rates, and recurrence rates in the bladder neck and prostatic urethra were determined and compared.
  • At a mean follow-up of 35.2 and 33.1 months in groups 1 and 2, respectively, only 1 patient developed recurrence in prostatic urethra or bladder neck in each group.
  • There were no statistically significant differences between the 2 groups in follow-up time, recurrence, progression or recurrence in the prostatic urethra, and bladder neck.
  • CONCLUSIONS: According to our results, simultaneous transurethral TURP and TURBT can be safely performed without increasing the risk of tumor recurrence in the prostatic urethra.
  • [MeSH-major] Cystectomy / methods. Neoplasm Recurrence, Local / epidemiology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Chi-Square Distribution. Cohort Studies. Combined Modality Therapy. Cystoscopy / methods. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Postoperative Complications / mortality. Postoperative Complications / pathology. Probability. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Rate. Treatment Outcome. Urethra / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19781747.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Charfi S, Moussa A, Njim L, Toffahi M, Hadhri R, Mahmoudi H, Zakhama A: [Micropapillary bladder carcinoma]. Prog Urol; 2006 Nov;16(5):607-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Micropapillary bladder carcinoma].
  • [Transliterated title] Carcinome micropapillaire de la vessie.
  • Micropapillary bladder carcinoma is a recently described, rare variant of urothelial carcinoma reputed for its poor prognosis.
  • The authors report the case of a 59-year-old man with invasive bladder tumour presenting with haematuria.
  • The authors discuss the clinicopathological and pathogenic features, treatment and clinical course of this tumour.
  • [MeSH-major] Carcinoma, Papillary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Hematuria / etiology. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175962.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


70. Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, Protheroe A, Macaulay VM: The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int; 2007 Dec;100(6):1396-401
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.
  • OBJECTIVE: To analyse bladder cancer biopsies and investigate the pattern of expression of the type 1 insulin-like growth factor receptor (IGF1R), a receptor tyrosine kinase that mediates tumour cell proliferation, motility and protection from apoptosis.
  • MATERIALS AND METHODS: Formalin-fixed specimens of bladder cancer (40 whole-mount, 80 cores on a tumour microarray) and normal bladder (15 samples) were stained immunohistochemically for the IGF1R.
  • The IGF1R expression was also measured by quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) on RNA extracted from fresh frozen bladder cancers (61) and benign bladder (12).
  • RESULTS: Of the 15 samples of normal bladder, 14 showed negligible (1+) or light (2+) IGF1R immunostaining.
  • Q-RT-PCR showed significantly higher levels of steady-state IGF1R mRNA in tumours (all cases, Ta-T4) than in normal bladder (P < 0.05), indicating up-regulation at the transcriptional level.
  • This difference was particularly evident when comparing normal urothelium with superficial (Ta-T1) or invasive (T2-4) tumours; only the latter showed significant IGF1R over-expression at the RNA level (P < 0.05 vs normal bladder).
  • CONCLUSION: The IGF1R is up-regulated in bladder cancer compared with non-malignant bladder, and might contribute to a propensity for invasion.
  • [MeSH-major] Neoplasm Proteins / metabolism. Receptor, IGF Type 1 / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645417.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601061
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


71. Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L: Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol; 2006 Oct;19(10):1289-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted papilloma of the urinary bladder: a molecular genetic appraisal.
  • Inverted papilloma of urinary bladder is an uncommon urothelial neoplasm.
  • The monoclonal origin demonstrated in the study of X-chromosome inactivation indicates the clonal process of inverted papilloma; however, the low incidence of LOH supports the view that inverted papilloma in urinary bladder is a benign neoplasm with molecular genetic abnormalities different from those of urothelial carcinoma.
  • [MeSH-major] Loss of Heterozygosity. Microsatellite Repeats / genetics. Papilloma, Inverted / genetics. Urinary Bladder Neoplasms / genetics. X Chromosome Inactivation
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Interferon-alpha / genetics. Male. Receptors, Androgen / genetics. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16862073.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Interferon-alpha; 0 / Receptors, Androgen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


72. Grima F, Golfier F, Raudrant D: [Clinicopathological correlation in bladder endometriosis]. Prog Urol; 2005 Jun;15(3):498-500
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological correlation in bladder endometriosis].
  • Bladder endometriosis is a rare site of a disease with very polymorphic clinical signs.
  • The authors report the case of a 30-year-old woman operated for bladder endometriosis who presented with recent menstrual macroscopic haematuria with primary infertility and deep dyspareunia.
  • Histological examination demonstrated bladder endometriosis sparing the urothelium.
  • Comparison with our histological series of bladder endometriosis demonstrated polymorphic lesions ranging from integrity to complete loss of the bladder mucosa, with no correlation with clinical features.
  • [MeSH-major] Endometriosis / pathology. Urinary Bladder Diseases / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16097157.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


73. Kavia R, Mumtaz F: Overactive bladder. J R Soc Promot Health; 2005 Jul;125(4):176-9
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local pathological or hormonal factors.
  • ApproximateLy 70% of men with bladder outflow obstruction will have some symptoms of OAB.
  • The exact pathophysiology of OAB in bladder outflow obstruction is yet to be elucidated; evidence to date points to changes in both the efferent and afferent innervation and the detrusor.
  • More specific treatment options for OAB in bladder outflow obstruction include relief of the obstruction with surgical (e.g. transurethraL resection of prostate) or pharmaceutical (e.g. a blockers) methods.
  • [MeSH-major] Urinary Bladder Diseases / therapy. Urinary Incontinence / therapy

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094929.001).
  • [ISSN] 1466-4240
  • [Journal-full-title] The journal of the Royal Society for the Promotion of Health
  • [ISO-abbreviation] J R Soc Promot Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Dyskinesia Agents; 0 / Muscarinic Antagonists; 0 / Muscle Relaxants, Central
  • [Number-of-references] 21
  •  go-up   go-down


74. Brooks RA, Wright JD, Powell MA, Rader JS, Gao F, Mutch DG, Wall LL: Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol; 2009 Jul;114(1):75-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.
  • OBJECTIVE: To determine the long-term effects of radical hysterectomy on bladder and bowel function.
  • Two contemporary controls who underwent extrafascial abdominal hysterectomy for benign disease were identified for each subject.
  • CONCLUSION: Urinary incontinence is relatively common after radical hysterectomy, but severe anorectal dysfunction is uncommon.
  • Radical hysterectomy does not appear to be associated with more long-term bladder or anorectal dysfunction than simple hysterectomy.
  • [MeSH-major] Hysterectomy / adverse effects. Intestinal Diseases / etiology. Urinary Bladder Diseases / etiology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Emotions. Female. Humans. Life Style. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Urinary Incontinence / epidemiology. Urinary Incontinence / etiology


75. Sun Y, He H, Ma Q, Wang XY, Yang L, He DL: [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis]. Zhonghua Yi Xue Za Zhi; 2005 Sep 14;85(35):2507-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
  • OBJECTIVE: To evaluate the sensitivity and specificity of BTAstat, NMP22, HA, Survivin, CD44v6, VEGF, and VUC in detection of bladder cancer.
  • METHODS: We detect VUC, BTAstat, NMP22, HA, Survivin, CD44v6, VEGF in the urine of 10 normal case (healthy volunteers), 11 benign urological diseases patients and 52 bladder cancer patients.
  • The overall sensitivity and specificity of urinary tumor markers were: 42.3% and 100% for VUC; 78.8% and 90.5% for BTAstat; 76.9% and 81.0% for NMP22; 86.5% and 90.5% for HA; 67.3% and 85.7% for Survivin; 50.5% and 85.7% for CD44 and 69.2% and 95.2% for VEGF.
  • CONCLUSION: Each marker had achieved its obvious clinical value in diagnosis of bladder cancer.
  • The sensitivity of all the markers was increased with the progression of tumor grades and clinical stages, except the CD44v6.
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321281.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Nuclear Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / nuclear matrix protein 22
  •  go-up   go-down


76. Song JW, DU LL, Zhao XW, Jing JX, Han CZ, Cui Y, Liu JW, Hao HL, Wang ZG, Mi ZG: [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder]. Zhonghua Zhong Liu Za Zhi; 2009 Apr;31(4):274-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
  • OBJECTIVE: To evaluate the expression and clinical significance of urinary nuclear matrix protein (NMP22) and cytokeratin 18 (CK18) for transitional cell carcinoma of the bladder.
  • METHODS: Urinary NMP22 and CK18 levels of 293 patients with transitional cell carcinoma of the bladder, 400 patients with non-transitional cell carcinoma of the bladder, and 105 bladder benign disease were analysed by enzyme-linked-immunosorbent assay (ELISA).
  • RESULTS: The levels of urinary NMP22 and CK18 in the patients with transitional cell carcinoma of the bladder (M = 17.3 U/ml, M(CK18) = 484.2 U/L) were significantly higher than those in the non-transitional cell carcinoma of the bladder (M = 6.8 U/ml, M(CK18) = 156.0 U/L) and the benign disease group (M(NMP22) = 2.3 U/ml, M(CK18) = 66.6 U/L) (P < 0.001).
  • The sensitivity and specificity of urinary NMP22 and CK18 were 79.2%, 88.6% and 78.2%, 82.9%, respectively, for transitional cell carcinoma of the bladder before any treatment.
  • The levels of urinary nmp22 and CK18 were significantly different among pathological grade G1, G2, G3, and stage Ta, T1, T2, T3 (P < 0.01).
  • CONCLUSION: NMP22 and CK18 are useful tumor marker for diagnosis of transitional cell carcinoma of the bladder and for monitoring the state of illness.
  • NMP22 and CK18 may become a new class of tumor markers, and to be the basis for development of a new assay with an increased efficacy for the detection and treatment of bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / urine. Keratin-18 / urine. Nuclear Proteins / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / urine. Carcinoma, Renal Cell / urine. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Prognosis. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615282.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Nuclear Proteins; 0 / nuclear matrix protein 22
  •  go-up   go-down


77. Lokeshwar VB, Cerwinka WH, Lokeshwar BL: HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res; 2005 Mar 15;65(6):2243-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion.
  • Hyaluronic acid and HYAL1-type hyaluronidase show high accuracy in detecting bladder cancer and evaluating its grade, respectively.
  • Hyaluronic acid promotes tumor progression; however, the functions of hyaluronidase in cancer are largely unknown.
  • In this study, we stably transfected HT1376 bladder cancer cells with HYAL1-sense (HYAL1-S), HYAL1-antisense (HYAL1-AS), or vector cDNA constructs.
  • In xenografts, there was a 4- to 5-fold delay in the generation of palpable HYAL1-AS tumors, and the weight of HYAL1-AS tumors was 9- to 17-fold less than vector and HYAL1-S tumors, respectively (P < 0.001).
  • Whereas HYAL1-S and vector tumors infiltrated skeletal muscle and blood vessels, HYAL1-AS tumors resembled benign neoplasia.
  • HYAL1-S and vector tumors expressed significantly higher amounts of HYAL1 (in tumor cells) and hyaluronic acid (in tumor-associated stroma) than HYAL1-AS tumors.
  • Microvessel density in HYAL1-S tumors was 3.8- and 9.5-fold higher than that in vector and HYAL1-AS tumors, respectively.
  • These results show that HYAL1 expression in bladder cancer cells regulates tumor growth and progression and therefore serves as a marker for high-grade bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / enzymology. Carcinoma, Transitional Cell / pathology. Hyaluronoglucosaminidase / biosynthesis. Urinary Bladder Neoplasms / enzymology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Apoptosis / physiology. Cell Cycle / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Extracellular Matrix / metabolism. Humans. Hyaluronic Acid / metabolism. Neoplasm Invasiveness. Neoplasm Transplantation. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / pathology. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781637.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 072821-06A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 9004-61-9 / Hyaluronic Acid; EC 3.2.1.35 / Hyaluronoglucosaminidase
  •  go-up   go-down


78. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, Lew S, Leibovitch I: Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer; 2007 Dec 25;111(6):517-24
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
  • BACKGROUND: Bladder cancer is among the 5 most common malignancies worldwide.
  • Patients with bladder cancer are closely followed with periodic cystoscopies and urine cytology analyses due to the significant risk of tumor recurrence.
  • The UroVysion fluorescence in situ hybridization (FISH) test demonstrated higher sensitivity over urine cytology in detecting bladder cancer by most comparative studies.
  • METHODS: In the current study, the diagnostic usefulness of a combined cytology and FISH analysis approach was tested using the Duet automatic scanning system in patients with benign urine cytology who were being monitored for recurrent urothelial carcinoma or being assessed for various urologic symptoms.
  • RESULTS: By combining the benefits of conventional cytology with molecular diagnostics, a more sensitive detection of bladder cancer was attained.
  • CONCLUSIONS: Given the absolute sensitivity and NPV of the combined analysis test, the management of patients with a negative combined analysis result might be revised and allow for more flexible assessment and management of bladder cancer patients relying more on urine bound tests.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / urine. Urine / cytology
  • [MeSH-minor] Cytodiagnosis. Female. Follow-Up Studies. Humans. In Situ Hybridization, Fluorescence. Male. Neoplasm Recurrence, Local / diagnosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963263.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


79. Hillard T: The postmenopausal bladder. Menopause Int; 2010 Jun;16(2):74-80
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The postmenopausal bladder.
  • The bladder and its surrounding structures are rich in estrogen receptors and there are demonstrable physiological and anatomical changes that occur around and immediately after the menopause.
  • The prevalence of many bladder symptoms, such as frequency, urgency and incontinence, does seem to increase around the menopause, but there is continuing debate over whether these effects are due to ageing, menopause or a combination of the two.
  • The impact of the menopause varies with individual symptoms; stress urinary incontinence being associated more with estrogen deficiency than urge incontinence which seems to be more age-related.
  • Based on these effects, it could be anticipated that estrogen replacement would have a positive effect on bladder symptoms.
  • It seems that topical estrogens do have some positive effects, particularly on symptoms of urgency, frequency and urge incontinence, the prevention of urogenital atrophy and in the prevention of recurrent urinary tract infections.
  • The possible explanations for this apparent contradiction are explored, but based on current evidence, it would appear preferable to use vaginal estrogens rather than systemic as part of the management of menopause-related bladder problems.
  • [MeSH-major] Estrogen Replacement Therapy. Postmenopause / physiology. Urinary Bladder / physiopathology. Urinary Incontinence / etiology. Urinary Incontinence / physiopathology
  • [MeSH-minor] Administration, Intravaginal. Age Factors. Female. Humans. Receptors, Estrogen / physiology. Receptors, Progesterone / physiology. Urinary Tract Infections / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729499.001).
  • [ISSN] 1754-0461
  • [Journal-full-title] Menopause international
  • [ISO-abbreviation] Menopause Int
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


80. Patrick DJ, Fitzgerald SD, Sesterhenn IA, Davis CJ, Kiupel M: Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification. J Comp Pathol; 2006 Nov;135(4):190-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of canine urinary bladder urothelial tumours based on the World Health Organization/International Society of Urological Pathology consensus classification.
  • One hundred canine urinary bladder urothelial (transitional cell) tumours, including roughly equal numbers of benign and malignant forms, were retrospectively categorized in accordance with the newly described human consensus classification of the World Health Organization/International Society of Urological Pathology (WHO/ISUP).
  • The tumours were reviewed and classified by three veterinary pathologists from Michigan State University and two human pathologists from the Armed Forces Institute of Pathology (AFIP).
  • Canine tumours, however, differed from human tumours in that the great majority showed extensive glandular differentiation (or metaplasia) and hyperplastic lesions tended to be more florid than those seen in human beings.
  • The various diagnoses and grades assigned to the tumours were highly consistent between all reviewing pathologists.
  • This paper presents the salient features of the new WHO and ISUP consensus classification and provides illustrations of the various tumour types that were directly applicable to the dog.
  • [MeSH-major] Dog Diseases / classification. Urinary Bladder Neoplasms / classification. Urinary Bladder Neoplasms / veterinary. Urothelium / pathology
  • [MeSH-minor] Animals. Consensus. Dogs. Humans. Neoplasm Staging. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054974.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


81. Zhang X, Gupta R, Nicastri AD: Bladder adenocarcinoma following gastrocystoplasty. J Pediatr Urol; 2010 Oct;6(5):525-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder adenocarcinoma following gastrocystoplasty.
  • Bladder augmentation with segments of small bowel (ileocystoplasty), large intestine (colocystoplasty) or stomach (gastrocystoplasty) has been used to treat patients with small or noncompliant bladders by increasing the capacity or compliance.
  • Carcinomas following gastrocystoplasty have been observed in the segments of stomach; however, to our knowledge, carcinoma arising in the residual native bladder has not been reported.
  • We report the first case of adenocarcinoma arising in the residual native bladder in association with intestinal metaplasia and dysplasia of bladder mucosa 17 years following gastrocystoplasty.
  • Intestinal metaplasia secondary to recurrent urinary infection, chronic inflammation, and some form of irritation may potentiate the development of native bladder adenocarcinoma.
  • Patients with gastrocystoplasty are at an increased risk for carcinoma in stomach segments and require close long-term follow up; however, the risk of carcinoma in native bladder is still unclear.
  • [MeSH-major] Adenocarcinoma / etiology. Urinary Bladder / surgery. Urinary Bladder Neoplasms / etiology. Urologic Surgical Procedures / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20392671.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Lebret T: [Infiltrating bladder tumours]. Rev Prat; 2007 Mar 31;57(6):630-40
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltrating bladder tumours].
  • [Transliterated title] Tumeurs infiltrantes de la vessie.
  • Invasive bladder tumours are defined as carcinomas infiltrating the muscular fibbers of the bladder wall.
  • The assessment of tumour extension includes a clinical examination and an abdominopelvic computed tomography.
  • In patients with in situ bladder cancers, this treatment results in a five-year specific survival of 90 percent.
  • After bladder resection, several types of urinary diversion may be considered.
  • The efficiency of the neobladder should be monitored regularly to ensure a satisfactory urinary voiding as well as continence acquisition, which can be achieved through auto-rehabilitation.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Cystectomy. Diagnostic Imaging. Humans. Neoplasm Invasiveness. Urinary Diversion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593787.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 10
  •  go-up   go-down


83. Waine E, Stott M: Changing treatments for overactive bladder. Nurs Times; 2008 Oct 14-20;104(41):45-8
MedlinePlus Health Information. consumer health - Overactive Bladder.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing treatments for overactive bladder.
  • Overactive bladder is a common urological diagnosis which is often untreated as patients fail to seek help for this embarrassing problem.
  • Elizabeth Waine and Mark Stott summarise the symptoms and investigations for overactive bladder and provide an overview of the treatments available.
  • [MeSH-major] Urinary Bladder, Overactive / drug therapy. Urinary Incontinence, Urge / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979960.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Neuromuscular Agents; 0 / Parasympatholytics; EC 3.4.24.69 / Botulinum Toxins, Type A
  • [Number-of-references] 20
  •  go-up   go-down


84. Morsi MI, Youssef AI, Hassouna ME, El-Sedafi AS, Ghazal AA, Zaher ER: Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. J Egypt Natl Canc Inst; 2006 Mar;18(1):82-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients.
  • AIM OF THE STUDY: This work aims to search for markers suitable for the screening of bladder cancer, which should be specific, sensitive, reproducible, non-invasive and at acceptable cost.
  • PATIENTS AND METHODS: The study included 50 patients diagnosed as bladder cancer (35 TCC, 15 SCC) of different stages and grades, 30 patients with various urothelial diseases, besides 20 apparently healthy subjects of matched age and sex to the malignant group.
  • RESULTS: For all parameters (telomerase, K19, K20 and cytology) the malignant group was significantly different from both the benign and the control groups.
  • CONCLUSION: K 19 may be used as a biological marker for the diagnosis of bladder cancer.
  • K19 could not be used for differential diagnosis of different types of bladder cancer, meanwhile it could be a marker for differentiation that decreases in less differentiated tumors.
  • As a tumor marker, K20 reflects inability to differentiate tumor type or grade in TCC, while in SCC of the bladder it is correlated with the grade.
  • As a method, RT-PCR is superior to immunostaining for the detection of bladder cancer, meanwhile K20 immunohistochemistry (IHC) results were much better than urine cytology as a bladder cancer screening test.
  • Haematuria and inflammation reduced the specificity of telomerase assay, which reduced its validity as a tumor marker of bladder cancer.
  • K19 and K20 are the best candidates as screening tests for the diagnosis of bladder cancer, representing the highest sensitivity and specificity, beside the radiological and histopathology.
  • [MeSH-major] Biomarkers, Tumor / urine. Keratin-18 / urine. Keratin-20 / urine. Telomerase / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] False Positive Reactions. Female. Humans. Immunohistochemistry. Male. Mass Screening / methods. Middle Aged. Neoplasm Staging. ROC Curve. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237854.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Keratin-20; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


85. Engholm G, Hakulinen T, Gislum M, Tryggvadóttir L, Klint A, Bray F, Storm HH: Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol; 2010 Jun;49(5):655-64
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964-2003 followed up to the end of 2006.
  • BACKGROUND: Previous studies have shown systematic differences between the Nordic Countries in population-based relative survival following a kidney or urinary bladder cancer diagnosis.
  • Comparison of bladder cancer over time and between Nordic registries is complicated by variable coding practices with respect to the inclusion of in situ cases with invasive tumours.
  • MATERIAL AND METHODS: Five-year relative survival of patients with urinary cancer diagnosed in the Nordic countries 1964-2003 and followed up for death through 2006 was studied and contrasted with developments in incidence and mortality.
  • RESULTS: The survival following bladder cancer was higher than for kidney cancer and highest for men.
  • Survival increased over the years in all countries, more for kidney cancer than bladder cancer.
  • Danish bladder cancer patient survival was in the last period 4% points lower among men and 10% points lower among women than in the other Nordic countries.
  • The differences were mainly found in the first year following diagnosis, where a higher excess mortality in Denmark was observed.
  • Survival decreased with higher age at diagnosis.
  • CONCLUSION: The increasing 5-year relative survival in all the Nordic countries for both kidney and bladder cancer are promising, but for kidney cancer a higher percentage detected coincidentally during an imaging investigation for other diseases could play a role.
  • Denmark had the lowest survival, despite their known practice of including benign conditions with invasive bladder cancers.
  • The lower Danish survival after kidney and bladder cancer in the first year after diagnosis could be due to later diagnosis on average, a higher co-morbidity from smoking-related diseases, and perhaps, less adequate cancer treatment and management in Denmark.
  • [MeSH-major] Kidney Neoplasms / mortality. Urinary Bladder Neoplasms / mortality
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Denmark / epidemiology. Female. Finland / epidemiology. Follow-Up Studies. Humans. Iceland / epidemiology. Incidence. Male. Mass Screening. Middle Aged. Mortality / trends. Neoplasm Staging. Norway / epidemiology. Registries. Risk Factors. Survival Analysis. Survival Rate / trends. Sweden / epidemiology

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156116.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. Hautmann RE: [Ileal bladder substitute]. Urologe A; 2008 Jan;47(1):33-4, 36-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileal bladder substitute].
  • The history of urinary diversion in general began in 1852 and started right away with continent diversion, i.e., ureterosigmoidostomy.
  • They replaced the bladder by an isoperistaltic ileal segment which was interposed between ureters and urethra in a female dog.
  • In 1951 Couvelaire reactivated this idea of an ileal bladder substitute.
  • Retrospectively many disappointing results of urinary diversion were often not caused by insufficient competence of the outlet mechanism, but because the intestinal reservoir maintained its peristaltic properties causing high pressure peaks.
  • Transsection of the circular intestinal musculature when performing bladder augmentation had already been published by Rutkowski in 1899, Tasker in 1953, and Giertz in 1957.
  • Reflux prevention in neobladders is even less important than in a normal bladder.
  • In these patients life is similar to that in individuals with a native lower urinary tract.
  • Until a better solution is devised orthotopic bladder reconstruction remains the best option for patients requiring cystectomy.
  • [MeSH-major] Urinary Diversion / history. Urinary Reservoirs, Continent / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1996 Dec;78(6):840-6 [9014706.001]
  • [Cites] J Urol. 2006 Jan;175(1):185-9; discussion 189 [16406905.001]
  • [Cites] J Urol. 1987 Nov;138(5):1150-4 [3312639.001]
  • [Cites] Ann R Coll Surg Engl. 1970 Jun;46(6):320-37 [5420581.001]
  • [Cites] Br J Urol. 1953 Dec;25(4):349-57 [13115674.001]
  • [Cites] Urol Res. 1985;13(5):243-7 [4060368.001]
  • [Cites] J Urol. 1953 Oct;70(4):600-4 [13097637.001]
  • [Cites] Ann Surg. 1943 Jan;117(1):106-9 [17858159.001]
  • [Cites] Arch Surg. 1969 Aug;99(2):223-31 [5794896.001]
  • [Cites] Urol Clin North Am. 1986 May;13(2):321-31 [3515728.001]
  • [Cites] Urologe A. 1987 Mar;26(2):67-73 [3296394.001]
  • [Cites] Eur Urol. 1976;2(1):8-12 [971687.001]
  • [Cites] J Urol. 2005 Jan;173(1):144-7 [15592057.001]
  • [Cites] J Urol. 1957 Dec;78(6):683-720 [13482070.001]
  • [Cites] Acta Chir Scand. 1957 Oct 4;113(3):218-28 [13478409.001]
  • [Cites] Eur Urol. 1988;14 Suppl 1:36-40 [3181240.001]
  • [Cites] J Urol. 2005 Feb;173(2):482-4 [15643221.001]
  • [Cites] J Urol. 2003 Mar;169(3):834-42 [12576795.001]
  • [Cites] J Urol Medicale Chir. 1951;57(6):408-17 [14889638.001]
  • [Cites] J Urol. 1996 Dec;156(6):1913-7 [8911354.001]
  • [Cites] World J Urol. 2006 Aug;24(3):305-14 [16830152.001]
  • (PMID = 18210063.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Carballo Alvarez M, Martínez Vilariño M, Llaga Rodríguez M: [Bladder cleansing]. Rev Enferm; 2008 Jan;31(1):27-30
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bladder cleansing].
  • [Transliterated title] Lavado vesical.
  • Bladder cleansings are administered in order to maintain the permeability of a probe and/or to eliminate an obstruction, be it a clot, urinary sand or detritus, by means of an infusion of intravenous fluid using sterile procedures through a bladder catheter.
  • This is a technique frequently used with patients undergoing genital-urinary surgery; it is not recommended for routine usage due to its high risk of associated infection.
  • Bladder cleansing can be continuous by means of a permanent bladder cleansing method or intermittent by means of an open or closed system.
  • [MeSH-major] Therapeutic Irrigation. Urinary Bladder Diseases / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497003.001).
  • [ISSN] 0210-5020
  • [Journal-full-title] Revista de enfermería (Barcelona, Spain)
  • [ISO-abbreviation] Rev Enferm
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


88. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Müller M: Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer; 2005 Aug 10;116(1):100-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.
  • Survivin is an inhibitor of apoptosis that has been suggested as a novel diagnostic/prognostic marker of bladder cancer.
  • In this study, survivin mRNA expression was measured by a sensitive real-time PCR assay in tumor tissue and urine from bladder cancer patients and assessed for its potential diagnostic and prognostic relevance.
  • Specimens from 53 patients with bladder transitional cell carcinoma (TCC) were analyzed, the controls being normal urothelial tissues (n = 14) and urine from benign disease patients (n = 22) and healthy individuals (n = 14).
  • Survivin transcripts were commonly detected in tumor tissues, but not in normal urothelium, and increasing mRNA levels correlate with progressing pathologic stage (p = 0.001) and grade categories (p < 0.004).
  • Higher levels of expression were associated with a reduced time to recurrence in noninvasive TCCs (p = 0.027, log-rank test) and a trend toward shorter disease-free survival in muscle-invasive tumors (p = 0.067).
  • Urinary survivin analysis detects TCC with higher sensitivity (68.6%) and equal specificity (100%) when compared with cytology (31.4% and 97.1%).
  • Our results indicate that tissue levels of survivin mRNA predict disease-free survival in noninvasive TCC and may have a role in bladder cancer progression.
  • [MeSH-major] Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / genetics. RNA, Messenger / analysis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Aged. Biomarkers, Tumor. Disease Progression. Disease-Free Survival. Humans. Inhibitor of Apoptosis Proteins. Neoplasm Proteins. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Urinary Bladder / chemistry. Urinary Bladder Diseases / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15761870.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


89. Nerli RB, Kamat GV, Alur SS, Koura A, Prabha V, Amarkhed SS: Bladder exstrophy in adulthood. Indian J Urol; 2008 Apr;24(2):164-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder exstrophy in adulthood.
  • BACKGROUND: We report our experience with the treatment of classic exstrophy of the bladder in a small series of seven adult males.
  • There are very few documented cases of adults presenting with exstrophy of bladder in literature.
  • MATERIALS AND METHODS: Adult males presenting with classic exstrophy of the bladder and complete epispadias underwent detailed evaluation including psychological assessment and counseling.
  • Prior to 2002 all patients underwent cystectomy of the existing bladder plate, with creation of catheterizable modified Mainz pouch.
  • Since 2002 patients were assessed for bladder reconstruction with augmentation ileocystoplasty, bladder neck reconstruction, and abdominal wall closure.
  • RESULTS: Seven adult males with classic exstrophy of the bladder and complete epispadias who had not received any previous treatment presented to us during the period 1991-2006.
  • Five of these underwent cystectomy with continent pouch and the remaining two underwent bladder reconstruction.
  • CONCLUSIONS: Surgical correction in adults with exstrophy of the bladder greatly improves self-esteem, confidence, and social relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1983 Aug;10(3):473-81 [6623735.001]
  • [Cites] Urology. 1973 Jul;2(1):20-4 [4148867.001]
  • [Cites] J Urol. 1966 Mar;95(3):356-9 [5906001.001]
  • [Cites] BJU Int. 2004 May;93(7):1037-42 [15142160.001]
  • [Cites] Urology. 2001 May;57(5):906-10 [11337291.001]
  • [Cites] J Urol. 2005 May;173(5):1728-31 [15821570.001]
  • [Cites] J Urol. 1999 Jun;161(6):1934-41 [10332476.001]
  • [Cites] J Urol. 1997 Mar;157(3):947-8 [9072609.001]
  • [Cites] Int Urol Nephrol. 1996;28(6):747-50 [9089040.001]
  • [Cites] J Urol. 1996 Dec;156(6):2037-40 [8911384.001]
  • [Cites] J Urol (Paris). 1992;98(1):64-5 [1527404.001]
  • [Cites] Teratology. 1987 Oct;36(2):221-7 [3424208.001]
  • [Cites] Urol Int. 1987;42(1):74-6 [3590408.001]
  • (PMID = 19468391.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2684262
  • [Keywords] NOTNLM ; Adult / augmentation ileocystoplasty / bladder reconstruction / epispadias / exstrophy bladder
  •  go-up   go-down


90. Behzatoğlu K, Durak H, Canberk S, Aydin O, Huq GE, Oznur M, Ozyalvaçli G, Yildiz P: Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma? Diagn Pathol; 2009;4:48

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor-like lesion of the urinary bladder: a report of two cases and literature review; giant cell tumor or undifferentiated carcinoma?
  • Giant cell tumor, excluding its prototype in bone, is usually a benign but local aggressive neoplasm originating from tendon sheath or soft tissue.
  • Visceral organ involvement including urinary bladder is rare.
  • Giant cell tumors in visceral organs usually accompany epithelial tumors and the clinical behavior of giant cell tumor in urinary bladder is similar to its bone counterpart.
  • Here, we report two cases of giant cell tumor located in urinary bladder in comparison with nine reported cases in the English literature.
  • One of the two cases we present had no concurrent urothelial tumor at the time of diagnosis but had a history of a low grade noninvasive urothelial carcinoma with three recurrences.
  • The histology of these two cases was similar to the giant cell tumor of bone and composed of oval to spindle mononuclear cells with evenly spaced osteoclast-like giant cells.
  • The histologic and immunohistochemical properties in our cases as well as their clinical courses were consistent with a giant cell tumor.
  • Consequently, tumors in urinary bladder showing features of giant cell tumor of bone may also be considered and termed "giant cell tumor".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] J Urol. 2002 Apr;167(4):1784 [11912413.001]
  • [Cites] J Orthop Sci. 2005 Nov;10(6):581-8 [16307183.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):161-71 [16322750.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):495-500 [16625096.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Feb;264(2):205-8 [16977452.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1209-15 [11743042.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1467-76 [12409723.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):440-3 [15043462.001]
  • [Cites] BMC Urol. 2004 Jun 18;4:7 [15207006.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):953-61 [15223968.001]
  • [Cites] Cancer. 1973 Mar;31(3):621-5 [4693590.001]
  • [Cites] Am J Clin Pathol. 1984 May;81(5):666-75 [6326564.001]
  • [Cites] J Urol. 1985 Mar;133(3):472-5 [3974000.001]
  • [Cites] J Urol. 1989 Jul;142(1):120-2 [2733086.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):43-8 [2432851.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):160-8 [1989464.001]
  • [Cites] Histopathology. 1990 Nov;17(5):413-8 [1706298.001]
  • [Cites] J Oral Pathol Med. 1999 Feb;28(2):54-8 [9950250.001]
  • (PMID = 20043822.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2811699
  •  go-up   go-down


91. Srivastava S, Roy R, Singh S, Kumar P, Dalela D, Sankhwar SN, Goel A, Sonkar AA: Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark; 2010;6(1):11-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy.
  • Urinary bladder cancer is a major epidemiological problem that continues to grow each year.
  • In this pilot study, utility of non-invasive (1)H NMR spectroscopy has been evaluated for probing the metabolic perturbations occurring in non-muscle invasive urinary bladder cancer. (1)H NMR spectra of urine of bladder cancer patients and controls (healthy and urinary tract infection/bladder stone) (n = 103) were acquired at 400MHz.
  • The cancer patients showed significant (p < 0.05) variations in concentration of hippurate and citrate as compared with healthy controls and benign controls.
  • The significant elevation in concentration of taurine was observed in urine of bladder cancer patients, which was below the sensitivity limit of 400MHz in control cases.
  • [MeSH-major] Biomarkers, Tumor / urine. Early Detection of Cancer / methods. Magnetic Resonance Spectroscopy / methods. Taurine / urine. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Carcinoma in Situ / diagnosis. Carcinoma in Situ / metabolism. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Protons. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20164538.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons; 1EQV5MLY3D / Taurine
  •  go-up   go-down


92. Matsushima M, Asakura H, Sakamoto H, Horinaga M, Nakahira Y, Yanaihara H: Leiomyoma of the bladder presenting as acute urinary retention in a female patient: urodynamic analysis of lower urinary tract symptom; a case report. BMC Urol; 2010;10:13
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyoma of the bladder presenting as acute urinary retention in a female patient: urodynamic analysis of lower urinary tract symptom; a case report.
  • BACKGROUND: Most bladder tumors are derived from the urothelium.
  • Benign mesenchymal tumors are rare.
  • Leiomyoma of the bladder is the most common benign neoplasm.
  • We present a case of leiomyoma of the bladder presenting with acute urinary retention in a female patient and report on the post-operative change in urodynamic findings.
  • CASE PRESENTATION: A 56-year-old woman presented with acute urinary retention.
  • Evaluations including ultrasound, magnetic resonance imaging, cystoscopy, and urodynamics contributed to a diagnosis of leiomyoma of the bladder.
  • Various medications were ineffective for solving her lower urinary tract symptoms; therefore, a transurethral resection was performed.
  • CONCLUSIONS: Leiomyoma of the bladder can cause female outlet obstruction.
  • [MeSH-major] Leiomyoma / complications. Leiomyoma / physiopathology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / physiopathology. Urinary Retention / etiology. Urodynamics
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Manometry. Middle Aged. Treatment Outcome. Urinary Bladder Neck Obstruction / etiology. Urologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurourol Urodyn. 2000;19(3):213-20 [10797578.001]
  • [Cites] Arch Esp Urol. 1991 Sep;44(7):795-8 [1953060.001]
  • [Cites] Urology. 1994 Feb;43(2):238-41 [8116123.001]
  • [Cites] Arch Esp Urol. 1995 Dec;48(10):987-90 [8588732.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):399-403 [9016215.001]
  • [Cites] Urology. 1998 Mar;51(3):408-11 [9510344.001]
  • [Cites] Urology. 1998 Dec;52(6):1142-3 [9836573.001]
  • [Cites] Urology. 2007 Oct;70(4):807-8 [17991566.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2008 Mar;19(2):232-5 [18310873.001]
  • [Cites] Can J Urol. 2009 Aug;16(4):4762-4 [19671234.001]
  • (PMID = 20684762.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2924335
  •  go-up   go-down


93. Mori Y, Maruyama T, Kondoh N, Nojima M, Yamamoto S, Shima H: [Orthotopic bladder substitution]. Hinyokika Kiyo; 2006 Jun;52(6):427-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orthotopic bladder substitution].
  • Orthotopic bladder substitution is the most desired form of urinary diversion because the patient can restore normal voiding after cystectomy.
  • Each method of bladder substitution has merits and demerits.
  • We compared the Mainz method and the Studer method of orthotopic bladder substitution we performed on 8 and 11 patients, respectively since 1992.
  • The Studer orthotopic ileal bladder substitution has given better results with better voiding pattern and less complication rates.
  • We consider the Studer ileal bladder substitution as a good technique to restore normal voiding after cystectomy.
  • [MeSH-major] Ileum / surgery. Urinary Diversion / methods. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16848355.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Kondo T, Kajimoto S, Okuda H, Toma H, Tanabe K: A case of granular cell tumor of the bladder successfully managed with extraperitoneal laparoscopic surgery. Int J Urol; 2006 Jun;13(6):827-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of granular cell tumor of the bladder successfully managed with extraperitoneal laparoscopic surgery.
  • Granular cell tumor is a benign neoplasm which frequently occurs in the oral cavity, skin, and subcutaneous tissue.
  • Granular cell tumor of the bladder is an extremely rare disease, and only nine cases have been reported.
  • We present here an additional case of granular cell tumor occurring in the bladder.
  • Unlike the other tumors reported, this tumor extruded into the Retzius' cavity.
  • Therefore, the tumor was successfully excised through extraperitoneal laparoscopic surgery.
  • The small tumor located in Retzius' cavity could be managed with extraperitoneal laparoscopic surgery.
  • [MeSH-major] Granular Cell Tumor / therapy. Laparoscopy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Humans. Male. Middle Aged. Urinary Bladder / pathology. Urinary Bladder / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16834673.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. Fatela-Cantillo D, Fernández-Suárez A, Menéndez V, Galán JA, Filella X: Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients. J Clin Lab Anal; 2005;19(4):167-71
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients.
  • We evaluated serum levels of soluble fragments of cytokeratin 19 (CYFRA 21-1) by immunoassay (ES-700; Roche Diagnostics, Mannheim, Germany) to assess its usefulness in the diagnosis and follow-up of bladder cancer.
  • The study included 39 patients with a diagnosis of transitional cell carcinoma (group 1) and 190 patients (group 2) with no evidence of tumor.
  • In group 2, 180 patients had a history of bladder cancer, and 10 had benign prostatic hyperplasia.
  • However, CYFRA 21-1 levels did not significantly differ between the patients with benign prostatic hyperplasia and those with bladder cancer (P=0.274).
  • CYFRA 21-1 values were higher in invasive bladder cancer compared to that detected in superficial stages (P=0.011).
  • CYFRA 21-1 serum levels do not provide enough sensitivity to justify its application in routine protocols for the detection and follow-up of bladder cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Keratins / blood. Urinary Bladder Neoplasms / blood. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Female. Follow-Up Studies. Humans. Keratin-19. Male. Middle Aged

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025482.001).
  • [ISSN] 0887-8013
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins
  •  go-up   go-down


96. Burks FN, Bui DT, Peters KM: Neuromodulation and the neurogenic bladder. Urol Clin North Am; 2010 Nov;37(4):559-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuromodulation and the neurogenic bladder.
  • Neurogenic bladder resulting from spinal cord injury and spina bifida has a profound impact on voiding function.
  • This article reviews the current literature with regards to electrical stimulation for neurogenic bladder and the clinical outcomes associated with sacral neuromodulation, pudendal neuromodulation, posterior tibial nerve stimulation, and the Finetech-Brindley posterior/anterior stimulator.
  • Neuromodulation, both electrical and physical, play an important role in the management of neurogenic bladder.
  • [MeSH-major] Electric Stimulation Therapy. Urinary Bladder, Neurogenic / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20955907.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


97. Otto W, Fritsche HM, Dirmeyer M, Burger M, Straub M, Rössler W, Wieland WF, Denzinger S: [Analysis of Clinical, Histopathological and Follow-Up Data on Transurethral Resections of the Bladder Performed during One Year at a University Centre]. Aktuelle Urol; 2010 Sep;41(5):316-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of Clinical, Histopathological and Follow-Up Data on Transurethral Resections of the Bladder Performed during One Year at a University Centre].
  • [Transliterated title] Untersuchung klinischer und histopathologischer Parameter sowie von Verlaufsdaten zur transurethralen Resektion der Harnblase an einem universitären Einzelzentrum.
  • INTRODUCTION: Transurethral resection of the bladder (TURB) is one of the most common surgical treatments in urology.
  • We examined the TURBs that had been carried out during one year for suspected bladder cancer (first findings and recurrence) and then analysed the further clinical courses of these patients within the first twelve months after TURB.
  • All initial and recurrence TURB were carried out with photodynamic diagnosis; the histological evaluation was performed at a university centre.
  • RESULTS: 71 % of the 118 initial resections performed during the observation period showed urothelial cell carcinoma of the bladder - pTa (61 %), pT1 (20 %), pT2-4 (17 %), Cis (2 %) while 60 re-TURBs in the whole period detected 17 % residual tumours.
  • Two patients (7 %) with initially benign findings developed bladder cancer in the follow-up period.
  • When bladder cancer is diagnosed in 7 % within one year after urocystitis has been detected in the initial TURB findings, regular follow-up examination of these patients, especially with certain risk profiles, has to be discussed.
  • [MeSH-major] Cystoscopy. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Neoplasm, Residual / pathology. Neoplasm, Residual / surgery. Retrospective Studies. Urinary Bladder / pathology. Urinary Bladder / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag Stuttgart * New York.
  • (PMID = 20669097.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Henderson E, Drake M: Overactive bladder. Maturitas; 2010 Jul;66(3):257-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overactive bladder.
  • Overactive bladder is a condition whose prevalence increases with ageing, and which can substantially impair quality of life.
  • It is defined by presence of urinary urgency, in the absence of other causes of similar problems.
  • The underlying mechanisms are incompletely understood, but may include increased excitability of smooth muscle, abnormal spread of excitation through the bladder wall, increased sensory nerve activity, and altered processing of information in the central nervous system.
  • Initial treatment comprises fluid advice and bladder training, followed by drug prescription.
  • Neuromodulatory techniques (sacral or tibial nerve stimulation) and reconstructive surgery (augmentation cystoplasty, detrusor myectomy or urinary diversion) can be offered in severe cases, but can have inadequate outcomes and significant implications.
  • [MeSH-major] Urinary Bladder / physiopathology. Urinary Bladder, Overactive / therapy. Urinary Incontinence, Urge / therapy

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20399043.001).
  • [ISSN] 1873-4111
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 54
  •  go-up   go-down


99. Drake MJ: The integrative physiology of the bladder. Ann R Coll Surg Engl; 2007 Sep;89(6):580-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The integrative physiology of the bladder.
  • Normal bladder function is complex, resulting from the co-operative interaction of numerous regulatory cell types, of which the interstitial cells and the peripheral neurones are particularly interesting.
  • Collectively, these comprise the myovesical plexus, which appears to confer structural and functional characteristics on the bladder loosely akin to those of the gut.
  • These include functional modularity, which gives rise to the potential for localised and propagating peristalsis-like movements in the bladder wall according to the prevailing physiological conditions.
  • Localised modular activity during filling may contribute to normal generation of sensation and exaggerated modular activity may give rise to urinary urgency.
  • Enhanced co-ordination of modular activity occurs in various models of detrusor overactivity; it leads to surges of contraction over a large part of the bladder wall, generating phasic changes in intravesical pressure.
  • During voiding, the myovesical plexus sustains detrusor contraction at the behest of the brainstem, monitoring state of bladder fullness as it does so, as a guide to the required duration for which it has to keep up the effort.
  • Accordingly, the bladder wall itself may house structures which render the bladder the effector level in a hierarchy of lower urinary tract regulation.
  • Dysfunction in these vital regulatory structures is an underestimated factor in the pathophysiology of clinical bladder problems.
  • [MeSH-major] Urinary Bladder / physiology. Urinary Bladder Diseases / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lab Invest. 2000 Oct;80(10):1491-9 [11045565.001]
  • [Cites] BJU Int. 2006 Sep;98(3):643-50 [16925766.001]
  • [Cites] J Urol. 2002 Aug;168(2):832-6 [12131376.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):19-30 [12525852.001]
  • [Cites] J Urol. 2003 Apr;169(4):1573-6 [12629418.001]
  • [Cites] BJU Int. 2003 May;91(7):702-10 [12699489.001]
  • [Cites] Exp Physiol. 2003 May;88(3):343-57 [12719759.001]
  • [Cites] J Urol. 2003 Jul;170(1):276-9 [12796704.001]
  • [Cites] J Physiol. 2004 Sep 1;559(Pt 2):567-81 [15235094.001]
  • [Cites] Neurourol Urodyn. 1993;12(5):463-71 [8252050.001]
  • [Cites] J Anat. 1997 Jan;190 ( Pt 1):125-34 [9034888.001]
  • [Cites] BJU Int. 2005 May;95(7):1002-5 [15839921.001]
  • [Cites] J Urol. 2006 Feb;175(2):771-6 [16407048.001]
  • [Cites] BJU Int. 2006 Mar;97(3):612-6 [16469036.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1332-7 [16686734.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):253-60 [16879490.001]
  • [Cites] Auton Autacoid Pharmacol. 2006 Jul;26(3):261-6 [16879491.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):401-3 [11502339.001]
  • (PMID = 18201471.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 19
  • [Other-IDs] NLM/ PMC2121225
  •  go-up   go-down


100. Nicola M, De Luca F: Bladder hernia. Arch Ital Urol Androl; 2006 Jun;78(2):77-8
MedlinePlus Health Information. consumer health - Bladder Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder hernia.
  • Bladder hernia is a rare condition, but crural herniation of the bladder into the scrotum is very rare.
  • A case of bladder hernia presenting with urological symptoms is described.
  • A 71-year-old man presented to the urological ward complaining for persistent frequency and nocturia associated with loss offorce and decrease of caliber of the urinary stream and the presence of a large mass of the right scrotum.
  • An IVP (intra venous pyelography) showed a large herniation of the bladder through the right inguinal canal into the scrotum.
  • The hernia sac, containing bowel and bladder, was dissectedfreefrom the spermatic cord and the testis and the hernia defect was repaired.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929610.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement